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ABSTRACT 
Jill McClain:  Mediation of the effects of obesity on coronary heart disease in a bi-ethnic 
cohort: the Atherosclerosis Risk in Communities (ARIC) Study 
(Under the direction of June Stevens, PhD) 
 
Excess adiposity is associated with physiologic risk factors for coronary heart disease 
(CHD), including dyslipidemia, high blood pressure and insulin resistance, however few 
studies have analyzed mediation of the obesity-CHD relationship by individual physiologic 
risk factors.  Mediation can be examined using structural equation modeling (SEM), which 
has several advantages over standard regression for analyses of mediation, including 
significance-testing of the individual indirect (mediated) effects.  We used data from the 
Atherosclerosis Risk in Communities (ARIC) Study, a longitudinal cohort of 15,792 African 
American and White adults aged 45-64 years at baseline (1987-1989) and followed through 
2005, to examine mediation of the effects of body mass index (BMI) on CHD hazard.  
Physiologic risk factors examined included total and high density lipoprotein (HDL) 
cholesterol, triglycerides, systolic and diastolic blood pressure (SBP, DBP) and insulin 
resistance.  The overall effect of BMI on CHD was curved, with a steeper slope at lower 
compared to higher BMI levels.  Mediated effects of BMI on CHD tended to be strongest 
through HDL cholesterol and insulin resistance.  Mediation was more moderate through total 
cholesterol and SBP, and was null through DBP and triglycerides.  In models that included 
all 6 hypothesized mediators, BMI was not directly associated with CHD.  We found no 
differences in mediation by race or gender.  Because antihypertensive medication use is 
highly prevalent in this cohort (31% at baseline), we explored the impact of medication use 
iv 
on our analyses involving blood pressure.  The associations of BMI with blood pressure and 
with CHD were markedly attenuated in participants taking antihypertensive medication 
compared to participants not taking antihypertensive medications, though the association of 
blood pressure with CHD was not different between the two groups.  When associations of 
BMI with SBP and DBP were compared in the same individuals before and after initiating 
treatment with antihypertensive medications, no differences were found.  Overall, these 
results highlight the complexity of analyses of blood pressure in persons being treated with 
antihypertensive medication and underscore the importance of traditional physiologic risk 
factors, particularly HDL cholesterol and insulin resistance, as mediators of the effect of 
obesity on CHD.   
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 I. INTRODUCTION 
A. Background 
Excess adiposity is associated with physiologic risk factors for coronary heart disease 
(CHD), including high blood pressure, elevated glucose and dyslipidemia.  Although many 
studies have examined the relationship between obesity and these risk factors, and between 
these risk factors and CHD events, few have analyzed mediation of the obesity-CHD 
relationship by individual risk factors, and even fewer have compared mediation across risk 
factors.  The lack of studies comparing risk factors as mediators is due, in part, to the scarcity 
of appropriate data on both measured metabolic mediators and CHD outcomes and, in part, to 
the limitations of traditional epidemiologic methods for this purpose.  Mediation is 
commonly analyzed in other fields using structural equation modeling (SEM).  SEM has 
several advantages over standard regression for analyses of mediation, including the 
specification of each path (and importantly, each non-path) among all variables in a given 
model and the ability to explicitly model the measurement error of variables.  In particular, 
SEM permits significance-testing of the indirect (mediated) effect.  
We know of no studies that have assessed racial and gender differences in the 
mediation of CHD.  Racial and gender differences have been found in the prevalences of 
obesity, CHD risk factors and CHD outcomes, as well as in the associations among these 
variables, but it is not clear whether risk factors mediate the adiposity-CHD relationship to 
the same degree across race and gender.  For example, African American women have higher 
incidence of CHD than white women, as well as a higher average body mass index (BMI) 
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and higher blood pressure, but is the higher incidence of CHD due to the effects of increased 
obesity on blood pressure, or are these health issues less associated with each other in 
African American women?   
A comparison of effects of obesity on CHD through blood pressure, glucose and 
lipids must consider how to incorporate medication use.  This methodological issue is 
especially important for blood pressure medication because of the high prevalence of 
antihypertensive medication use among middle-aged Americans.  Hypertension in obese 
individuals is known to be more resistant to antihypertensive treatment than in normal weight 
individuals (Pi-Sunyer 2007), but it is not known if the relationship between BMI and blood 
pressure in persons taking antihypertensive medication is similar to that in persons not taking 
medication.  This issue is not only of methodological value, but of substantive interest as 
well.  Therefore we will explore this topic in order to inform our primary analyses and to 
better understand the impact of medications. 
B. Research aims 
The aims of this research were as follows. 
1.  Primary Aim – Examine and compare the role of physiologic risk factors as 
mediators of the relationship between body mass index and CHD in a bi-ethnic cohort 
The physiologic risk factors examined were: total and high-density lipoprotein (HDL) 
cholesterol, triglycerides, systolic and diastolic blood pressure, and insulin resistance. 
1.a. Examine and compare physiologic risk factors individually as mediators of the 
effect of obesity on CHD 
1.b. Examine and compare physiologic risk factors in combination as mediators of 
the effect of obesity on CHD 
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1.c.  Determine if mediation of the obesity-CHD relationship differs by race and/or 
gender  
2.  Secondary Aim – Investigate the impact of antihypertensive medication use 
on relationships of BMI with blood pressure and CHD 
2.a. Determine if antihypertensive medications modify the cross-sectional 
associations between obesity and blood pressure 
2.b. Explore how antihypertensive medications affect mediation of the obesity-
CHD relationship by blood pressure 
Analyses used data from the Atherosclerosis Risk in Communities (ARIC) Study, a 
cohort of African American and White adults aged 45-64 at baseline (1987-1989).  Follow-
up data on fatal and non-fatal CHD events and procedures were available through 2005.  The 
cohort at baseline comprised 15,792 subjects.  To our knowledge, this is the first study to use 
structural equation modeling to examine physiologic risk factors as mediators of the 
adiposity-CHD relationship, as well as the first to systematically examine differences in 
mediation across race-gender groups.
 
 II. LITERATURE REVIEW 
A. Obesity and the risk of coronary heart disease 
1. Obesity 
The prevalence of overweight and obesity (BMI ≥ 25 kg/m2) together (hereafter 
“overweight”) among U.S. adults was 66% as of 2003-2004, with 32% obese 
(BMI ≥ 30 kg/m2) and 4.8% extremely obese (BMI ≥ 40 kg/m2).  Among non-hispanic 
African American adults, overweight was 76% and obesity was 45%.  All of these figures 
represent increases from 1999-2000 (Ogden, Carroll et al. 2006).   
Both general adiposity, usually measured by BMI, and body composition, measured 
in various ways, have been shown to adversely affect health (Pi-Sunyer 1993; Stevens 1995; 
Harris and Stevens 1998; Okosun, Liao et al. 2000; Kenchaiah, Evans et al. 2002; Bigaard, 
Tjonneland et al. 2003; Okura, Nakata et al. 2004; de Koning, Merchant et al. 2007; 
Janiszewski, Janssen et al. 2007).  Although relative risks associated with obesity are usually 
modest, population attributable risks are often dramatic due to the extremely high prevalence 
of this disorder.  Recent estimates of the deaths attributable to obesity in the U.S. range from 
112,000 to 414,000 per annum (Mokdad, Marks et al. 2004; Flegal, Graubard et al. 2005; 
Mokdad, Marks et al. 2005).    
2. Coronary heart disease 
In 2004, about 16 million U.S. adults (7.3% of the population) had prevalent 
Coronary heart disease (CHD).  There were 865,000 incident (new and recurrent) myocardial 
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infarctions (MI) in the U.S.  CHD is the largest single cause of death in the U.S., with 
452,327 deaths in 2004 (one of every 5 deaths) (AHA 2007).   
3. Obesity’s association with CHD 
Obesity has been shown in prospective studies to increase the risk of CHD events 
(Manson, Colditz et al. 1990; Pi-Sunyer 1993; Jousilahti, Tuomilehto et al. 1996; Kannel, 
Wilson et al. 2002; Kenchaiah, Evans et al. 2002; Bigaard, Tjonneland et al. 2003; Batty, 
Shipley et al. 2006; Kim, Meade et al. 2006; Mann, Lee et al. 2006).  In a large prospective 
Danish study, BMI predicted CHD events for a given waist circumference (Bigaard, 
Tjonneland et al. 2003).  BMI predicts CHD in the ARIC study (Folsom, Stevens et al. 
1998).   
4. Physiologic risk factors for CHD 
The effects of overweight on CHD are understood to occur at least partly through 
several physiologic risk factors, especially dyslipidemia, elevated blood sugar and high blood 
pressure.  The prevalences of obesity and selected CHD risk factors in the U.S. over the last 
45 years are shown in Figure 2.1. 
a. 
Hypertension 
Definitions and prevalence 
Hypertension is defined by the 7th report of the Joint National Committee on 
Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7) as a 
systolic blood pressure (SBP) of 140 mmHg or higher or a diastolic blood pressure (DBP) of 
90 mmHg or higher (see Table 2.1).  An SBP of 120-139 mmHg or a DBP of 80-89 mmHg is 
considered pre-hypertension.  Thirty percent of U.S. adults 20 years and over had high blood 
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pressure or were on antihypertensive medication in 1999-2002; another 28% of U.S. adults 
are pre-hypertensive (Centers for Disease Control 2007).   
Although hypertension prevalence had declined in the U.S. from the 1970s to the 
1990s, it appears to be on the rise again (Figure 2.2, above) (Hajjar, Kotchen et al. 2006; 
Ong, Cheung et al. 2007).  Antihypertensive medication use has risen markedly in the last 
decade, especially among overweight and obese individuals (Figure 2.2). 
Dyslipidemia 
Dyslipidemia is defined by the Third Report of the National Cholesterol Education 
Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults Adult Treatment Panel III (ATP III) as high total (≥ 240 mg/dL) or 
LDL cholesterol (≥ 160 mg/dL), low HDL cholesterol (< 40 mg/dL in men; < 50 mg/dL in 
women), and/or high triglycerides (TG) (≥ 200 mg/dL) (NCEP Expert Panel 2002).  There 
were 36.6 million U.S. adults (17% of the population) with total cholesterol over 240 mg/dL 
and over 100 million (48%) with total cholesterol over 200 mg/dL in 2004 (Rosamond, 
Flegal et al. 2007).  The prevalence of high LDL cholesterol was 13%, but only 29% had 
LDL in the optimal range (< 100 mg/dL) (Hyre, Muntner et al. 2007), and 17% of adults had 
HDL < 40 mg/dL (Rosamond, Flegal et al. 2007).  Geometric mean triglycerides rose from 
114 mg/dL at the 1976-80 U.S. National Health and Nutrition Examination Survey 
(NHANES) survey to 122 mg/dL at the 1999-2002 survey (Carroll, Lacher et al. 2005).  
About 24% of men and 16% of women age ≥ 40 had TG ≥ 200 mg/dL in 1999-2002 (Kim, 
Alley et al. 2006).  
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Insulin resistance and diabetes mellitus 
Diabetes Mellitus occurs when pancreatic beta cells cannot provide sufficient insulin 
to control blood sugar.  It is defined as a fasting blood glucose ≥ 126 mg/dL or a non-fasting 
glucose ≥ 200 mg/dL.  Fifteen million U.S. adults (7.1%) had physician-diagnosed diabetes 
in 2004, and 5 million (2.4%) were estimated to have undiagnosed diabetes.  Another 56.5 
million (27.6%) were estimated to have pre-diabetes (fasting glucose ≥ 110 mg/dL).  Type 2 
diabetes is preceded by insulin resistance, which occurs when body cells become less 
sensitive to insulin’s effects.  Initially, glucose levels do not change because insulin rises 
sufficiently to keep glucose within a normal range.  Increasing insulin resistance of the cells 
and eventual decrease in pancreatic function result in frank diabetes.  Elevated insulin 
resistance therefore precedes elevated glucose in the onset of diabetes and can be a useful 
tool in assessing cardiovascular (CVD) risk.  Insulin resistance is measured by means of the 
hyperglycemic euglycemic clamp (DeFronzo, Tobin et al. 1979), but can be approximated by 
the homeostasis model assessment, which multiplies glucose by insulin and divides by a 
constant (Wallace, Levy et al. 2004).   
5. Body mass index predicts physiologic risk factors 
Although absolute levels of some physiologic risk factors, including cholesterol and 
blood pressure, have fluctuated over the past several decades, overweight and obese persons 
continue to have higher levels of these factors than non-overweight persons, especially 
diabetes and hypertension.  The odds of hypertension in NHANES 2003-04 were 1.7 (1.2-
2.5) for overweight (compared to normal weight) and 3.4 (2.5-4.6) for obesity, after 
adjustment for age, sex, race and education.  The US Behavioral Risk Factor Surveillance 
System found an approximately 3.5-fold risk for diabetes in individuals with a BMI of 
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30 - < 40 kg/m2 compared to normal weight and an approximately 7-fold risk in those with a 
BMI ≥ 40 kg/m2, with similar increased risks for hypertension; the increased risk of high 
cholesterol was about 1.9 in both obese groups (Mokdad, Ford et al. 2003).  In a population-
based sample of Canadians, BMI was associated with blood pressure, blood lipids and 
diabetes mellitus (Ledoux, Lambert et al. 1997).  In an analysis from NHANES III, BMI was 
significantly correlated with serum lipids, glucose and blood pressure, and predicted odds of 
having one or more CVD risk factors in all race-gender groups (Zhu, Heshka et al. 2004).     
6. Physiologic risk factors predict CVD 
a. 
There is no doubt that high blood pressure is a causal contributor to, as well as an 
indicator of, atherosclerosis.  High blood pressure is a significant risk factor for stroke, 
coronary heart disease events, and cardiovascular and total mortality, independent of other 
risk factors (Lloyd-Jones 2007).  Treatment of high blood pressure has been shown to reduce 
the incidence of all of these (Turnbull 2007).  High blood pressure may directly damage the 
heart, making it less able to respond to increased demand (Labarthe 1998).  Further, 
atherosclerosis and insulin resistance, which are independently associated with obesity, can 
contribute to hypertension (Pi-Sunyer 2007).  In ARIC, even normal and high normal blood 
pressure levels are associated with increased CVD incidence, especially among obese 
individuals (Kshirsagar, Carpenter et al. 2006).  Lowering blood pressure with 
antihypertensive medication reduces CVD risk (Collins 1994). 
Hypertension 
b. 
LDL-cholesterol is one of the better understood risk factors for CVD.  Low-density 
lipoproteins carry cholesterol through the endothelial cells and into the intimal layer of the 
Dyslipidemia 
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arterial wall.  Within the intima, byproducts of the oxidation of LDL damage endothelial 
cells and convert macrophages into foam cells, causing additional damage and precipitating 
formation of atherosclerotic plaques (Labarthe 1998).  There is abundant literature 
associating LDL-cholesterol levels with increased risk of CVD and mortality, and elevated 
LDL-cholesterol is the primary target of the NCEP ATP III (NCEP 2001; Grundy, Cleeman 
et al. 2004).  Gene-induced reductions in LDL lead to substantially lower risk of CHD 
(Cohen, Boerwinkle et al. 2006). 
High-density lipoproteins carry cholesterol out of the intimal layer of the arterial wall, 
counterbalancing the effects of low-density lipoproteins (Labarthe 1998).  As with high 
LDL-cholesterol, low HDL-cholesterol has been well documented as an independent risk 
factor for CVD in adults.  The NCEP ATP III identifies HDL cholesterol below 40 mg/dL as 
a risk factor for CHD, and levels at or above 60 mg/dL as a “negative” risk factor (i.e., high 
HDL removes one other risk factor from an individual’s risk count) (NCEP 2001).  
Triglycerides are mostly transported in the body as part of very-low-density 
lipoproteins.  Triglyceride level has been shown to be an independent predictor of risk of 
myocardial infarction in men (Stampfer, Krauss et al. 1996), of accelerated atherogenesis and 
cardiovascular mortality in women (Tanko, Bagger et al. 2005), and of CVD in both genders 
(Austin 1997).  The mechanism for the independent contribution of triglycerides to CVD is 
not fully understood.  One possible mechanism is through direct accumulation in the vessel 
wall (Forrester 2001).   
Total cholesterol is the sum of LDL, HDL and very-low-density lipoproteins 
(VLDL).  LDL and VLDL are usually not measured directly, but VLDL can be estimated as 
one fifth triglycerides and LDL can then be calculated from total, HDL and estimated VLDL.  
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Despite being a combination of both “good” and “bad” cholesterol, total cholesterol predicts 
heart disease and is part of the Framingham risk score (D'Agostino, Vasan et al. 2008).   
In the ARIC study, total and HDL cholesterol and triglycerides (in women) predict 
incident CHD (Sharrett, Ballantyne et al. 2001; Chambless, Folsom et al. 2003; McNeill, 
Rosamond et al. 2005).    
c. 
Diabetes and its precursors – glucose intolerance and hyperinsulinemia – contribute 
to cardiovascular disease.  In addition, hyperinsulinemia, (present in type 2 diabetes as long 
as the pancreatic beta cells continue functioning reasonably well) affects atherogenesis 
directly due to effects on synthesis of lipids and connective tissue, growth and persistence of 
lipid lesions, and on sterol and LDL-cholesterol activity, and indirectly through effects on 
blood lipids and blood pressure.  Mortality due to diabetes was 72.8 thousand in 2004 
(Rosamond, Flegal et al. 2007). 
Insulin resistance and diabetes 
Diabetes is associated with incident CHD in ARIC.  The association is lower in 
African Americans, but because of the higher prevalence of diabetes in that population, the 
percent of CHD cases attributable to diabetes was higher (Folsom, Szklo et al. 1997).  
Among diabetics in ARIC, poor glycemic control is associated with severe peripheral arterial 
disease (Selvin, Wattanakit et al. 2006).   
7. Obesity, physiologic risk factors and CHD in ARIC 
Numerous studies of predictors of CHD have been published using data from the 
ARIC study.  BMI is associated with CHD (Folsom, Stevens et al. 1998), as are diabetes 
(Folsom, Szklo et al. 1997), LDL, HDL and total cholesterol, triglycerides (Sharrett, 
Ballantyne et al. 2001; McNeill, Rosamond et al. 2005) and blood pressure (Chambless, 
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Folsom et al. 2003; Kshirsagar, Carpenter et al. 2006).  The association with diabetes was 
weaker in African Americans, but because of the higher prevalence of diabetes in that 
population, the percent of CHD attributable to diabetes was higher.   
8. Obesity, physiologic risk factors and CHD outcomes vary by race 
African Americans have a shorter life expectancy than Whites and suffer higher rates 
of many chronic diseases (Kochanek and Smith 2004; NCHS 2004; CDC 2005).  Racial 
differences have been found in the prevalences of obesity (Li, Ford et al. 2007; Ogden 2007), 
CHD risk factors (Winkleby, Kraemer et al. 1998; Sundquist, Winkleby et al. 2001) and 
CHD outcomes (Jones, Chambless et al. 2002; American Heart Association 2008), as well as 
in the associations among these variables (Despres, Couillard et al. 2000; Harris, Stevens et 
al. 2000; Jones, Chambless et al. 2002; Carnethon, Lynch et al. 2006; Shai, Jiang et al. 2006; 
Abell, Egan et al. 2008).   
Differences in body composition between White and African American populations 
have long been noted (Merz, Trotter et al. 1956; Wagner and Heyward 2000).  Both the 
Charleston Heart Study (Stevens, Plankey et al. 1994) and the ARIC study (Duncan, 
Chambless et al. 1995) have shown that, at the same BMI, African Americans had smaller 
abdominal circumferences than Whites.  Using computed tomography, Conway et al. found 
that obese African American women had 23% less visceral fat than obese White women with 
similar WHR measurements (Conway, Yanovski et al. 1995). 
Further, there is evidence to indicate that the metabolic consequences of fat 
distribution may differ by ethnicity.  Ethnic differences have been noted in the association of 
visceral adipose tissue or waist-to-hip ratio (WHR) with blood pressure, plasma lipids and 
glucose and insulin kinetics (Dowling, Fried et al. 1991; Conway, Yanovski et al. 1995).  
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Generally, the associations between the index of fat distribution and the outcome were 
weaker in African Americans compared to Whites.   
There may also be differences in effects of treatment; among African Americans and 
Whites taking antihypertensive medications, African Americans have poorer blood pressure 
control despite being on more classes of medications (Safford, Halanych et al. 2007; 
Ostchega 2008).  Mortality rates from CHD are much higher in African Americans than in 
Whites (Clark, Ferdinand et al. 2001). 
Despite the many known differences, little is known about the interplay among 
obesity, physiologic risk factors and incident CHD.  There is some evidence that the 
relationships may differ by race.  For example, diabetes is more prevalent in African 
Americans than in Whites, but it is less predictive of CHD (Folsom, Szklo et al. 1997).  
Further, since the traditional physiologic risk factors were first identified in a largely White 
cohort (Framingham), it may be that these risk factors are not as relevant in other groups as 
in Whites.  Unfortunately, few longitudinal studies with hard CVD outcomes have included 
sufficient African Americans for racial comparisons.    
B. Effects of antihypertensive medication on analyses of blood pressure 
Medication use can present a methodological problem for analyses involving 
continuous blood pressure because the unmedicated blood pressure value is unobservable.  
When blood pressure is the outcome, the underlying unobserved value is likely to be the 
value of interest, and the reduced observed value in unmedicated individuals can attenuate 
the observed effects of risk factors in a population-based sample.  Common approaches to 
this problem are adjustment for medication use as a covariate or exclusion of medicated 
subjects from the analysis.  Exclusion will reduce power and generalizability and has the 
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potential to cause substantial bias because of the high prevalence of antihypertensive 
medication use (18% of all U.S. adults (Cutler, Sorlie et al. 2008) and 45% of those aged 60 
and over (Ostchega, Dillon et al. 2007) (author’s calculations from tables in cited 
references)).  Statistical adjustment is problematic because, although medication use lowers 
blood pressure at the individual level, it may be correlated with increased blood pressure in a 
community sample. In this case, a medication use variable functions as an indicator of 
hypertension rather than reflecting effects of medication on blood pressure, and adjustment 
for the medication use variable will not correctly account for confounding (Tobin, Sheehan et 
al. 2005).  Tobin et al. used simulated data to compare a variety of methods for handling 
treatment effects on blood pressure as an outcome variable (Tobin, Sheehan et al. 2005).  
They showed that some methods for imputing the underlying untreated value of blood 
pressure result in very little loss in power or bias.   
When blood pressure is the exposure variable, handling of treatment depends on 
whether the analyst is interested in the blood pressure experienced at the time of 
measurement, or in some proxy of adult lifetime blood pressure.  In the former case, 
treatment can be ignored; for the latter, a value in between the unmeasured underlying value 
and the measured treated value might be preferred, though such a value will be difficult to 
determine.  Lowering blood pressure with antihypertensive medication reduces CVD risk 
(Collins 1994), but the treated individual is likely still at higher risk due to historical 
exposure to higher blood pressure, and medications may not reduce average daily blood 
pressure to the same degree that blood pressure measured at the physician’s office is reduced 
(Chau, Bauduceau et al. 1992). 
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Since almost a third of ARIC participants were taking antihypertensive medication at 
baseline, effects of medication use on observed associations could be substantial for the 
analyses proposed here.  Many factors influence the effect of treatment (Chobanian, Bakris et 
al. 2003), including body mass index (Cushman, Ford et al. 2002; Pi-Sunyer 2007).  It will be 
important to understand the effects of treatment in this cohort and the association of 
treatment with other variables in order to determine the best methodology for handling 
treatment in these analyses. 
C. Analyses of mediation of the adiposity-CVD relationship 
1. Overview 
A number of cohort studies have examined mediation of the relationship between 
CVD and weight-related variables (Table 2.3).  The majority of such studies assessed 
mediation simply by controlling for the hypothesized mediators in a regression model  and 
then reporting the effect of the weight/adiposity variable with and without the mediator(s).  
Most papers focused on whether overweight was still significant after potential mediators 
were added, rather than on assessing mediation itself.  In many cases mediators were added 
as a block, though some added mediators individually.  None compared mediation in African 
Americans versus Whites. 
The adiposity exposure variable was usually BMI.  Other adiposity measures 
examined were waist circumference, skinfolds, waist-to-hip and skinfold ratios, and change 
in weight.  Mediators examined were blood lipids (total, HDL and LDL cholesterol, 
Lipoprotein(a), triglycerides), blood pressure (SBP, DBP and hypertension status), glucose, 
diabetic status, and inflammatory markers (C-reactive protein, von Willebrand factor, 
fibrinogen, factor VII).  In most studies, the overall relationship between the adiposity 
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variable and the outcome was positive (linear, U or J-shaped), as expected.  In a few cases, 
the relationship was inverse, but these were in sick or older cohorts.   
The majority of the papers found that the mediators assessed attenuated but did not 
eliminate the relationship between overweight and the outcome.  A meta-analysis of 21 
cohort studies (Bogers, Bemelmans et al. 2007) found a relative risk (RR) for a 5-unit change 
in BMI of 1.27 (95% CI: 1.21, 1.33) without and 1.15 (95% CI: 1.11, 1.19) with BP and 
cholesterol in the model.  A minority found that the mediators eliminated the association 
between overweight and the outcome (this often represented a similar absolute effect on the 
numbers as in the studies where the effect was not eliminated, but with a wider confidence 
interval).  Rarely, the mediators had no attenuating effect.  Since mediators were generally 
added as a block or successively, it is difficult to conclude from these studies which were 
more important.  There were six papers that tested the mediators individually.  Of these, four 
had CHD as the outcome.  These four papers are described in detail below. 
2. Papers assessing mediation of the adiposity-CHD relationship 
Manson et al (Manson, Colditz et al. 1990) used data from the Nurses’ Health Study 
to assess mediation of the adiposity-CHD relationship.  The mediators they examined were a 
“history of hypertension, diabetes and hypercholesterolemia”.  BMI was positively associated 
with nonfatal MI and fatal CHD, though RRs became significant only above a BMI of 
25 kg/m2.  A history of hypercholesterolemia slightly attenuated the relationship for 
BMIs ≥ 25 kg/m2.  This study differs slightly from most others in that weight, height and 
history of the mediators were self-reported rather than measured.  Kim et al assessed BMI 
and various skinfold measures as predictors of fatal CHD in the Northwick Park Heart Study 
(Kim, Meade et al. 2006).  In separate models for each exposure (BMI and forearm, triceps, 
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subscapular and suprailiac skinfolds), they successively added age, smoking, total 
cholesterol, SBP, fibrinogen and factor VII.  The addition of cholesterol to a model with age 
and smoking strengthened rather than attenuated the RR for the exposure.  The further 
additions of SBP, fibrinogen and factor VII attenuated, strengthened and attenuated the RR, 
respectively.  Jousilahti et al examined the relationship between BMI and CHD mortality in 
Finnish men and women aged 30-59 (Jousilahti, Tuomilehto et al. 1996).  While total 
cholesterol was significant in a model with BMI, the addition of cholesterol did not attenuate 
the crude relationship between BMI and CHD mortality.  The addition of blood pressure did 
attenuate (and inconsistently eliminated, depending on gender and age group) the RR for 
BMI (in models with and without smoking and cholesterol). 
Tanne et al assessed hazard ratios for death from CHD and stroke in male Israeli civil 
servants (Tanne, Medalie et al. 2005).  Exposures were BMI, subscapular skinfolds and the 
skinfold ratio (SFR - subscapular to triceps).  Their models adjusted for A) age, B) age + 
SBP, and C) age, SBP, diabetes, smoking and SES.  The addition of SBP attenuated and 
eliminated the RRs for each of the main effects on both outcomes, except for the effect of 
BMI on CHD.  The addition of diabetes, smoking and SES (model C) resulted in little change 
from the model with age and SBP. 
D. Preliminary studies 
In an analysis of mediation, principles of causal inference dictate that the exposure 
should occur prior to the mediator, but an interval of several years between the measurement 
of exposure and mediator may be too long if the mediator responds quickly to the exposure.  
Many CHD risk factors respond relatively rapidly to weight change (days or weeks), but the 
average interval between examinations in the ARIC study is approximately 3 years.  To 
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inform our decision about whether to use physiologic risk factors measured at the same or the 
subsequent study examination, we compared the strength of association of two 
anthropometric measures – BMI and waist circumference – with systolic and diastolic blood 
pressure, serum glucose, total, HDL and LDL cholesterol, and triglycerides (log-transformed) 
in cross-section and longitudinally (3-year lagged).   
We created a “stacked” ARIC dataset with 27,623 observations.  We ran linear mixed 
models using BMI or waist as the predictor, adjusting for age, sex, race, field center, 
education, relevant medications, smoking, and drinking. We used Wald tests to test 
differences between the cross-sectional and longitudinal analyses.  
BMI and waist were significantly associated with all of the risk factors, except for 
total cholesterol in the longitudinal analysis (Table 2.4).  Though differences were not always 
statistically significant, the associations of BMI and waist with risk factors measured in 
cross-section were generally larger than longitudinally.  This suggests that the association 
between obesity and the studied risk factors may be reduced when examined across a lag 
time of several years.  In the mediation analyses, therefore, we used risk factors measured at 
the same time as adiposity.  We recognize that this approach has some weaknesses.  For 
instance, associations might be more subject to reverse causation when cross sectional data 
are used.  Nevertheless, given the available data and our knowledge of the variables, we think 
that contemporaneous risk factor levels are a better indicator of the effect of obesity than is 
the level of the risk factor 3 years later.  
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Figure 2.1: Prevalence of selected CHD risk factors in the U.S. population from 1960-
2006 
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Table 2.1.  JNC 7 definitions and US prevalence of high blood pressure 
JNC 7 definitions SBP 
(mmHg) 
 DBP 
(mmHg) 
U.S. Prevalence 
in 1999-2002 
Normal blood pressure <120 and <80 42% 
Pre-hypertension 120-139 or 80-89 28% 
Stage 1 Hypertension 140-159 or 90-99 
30%* 
Stage 2 Hypertension ≥160 or ≥100 
*Had high blood pressure or were on medication for high blood pressure. 
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Figure 2.2:  Prevalence of antihypertensive medication use (by weight status), 
hypertension and high blood pressure in U.S. National Health Examination Surveys 
from 1960-2000 
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Table 2.2.  Prevalences of selected characteristics in the U.S. by race and gender 
(highest value in bold)* 
 Women  Men 
Source African 
American 
White African 
American 
White 
Abdominal obesity (WC 
>102cm in men or >88cm in 
women) 
76% 58% 35% 45% 
NHANES 2003-04 
(Li, Ford et al. 
2007) 
Overweight or obese 
(BMI ≥ 25 kg/m2) 80% 58% 67% 71% 
AHA Heart Disease 
and Stroke 
Statistics – 2008 
Update (data from 
2005) 
Obesity (BMI ≥ 30 kg/m2) 51% 31% 31% 30% 
Diabetes 13% 5.6% 11% 6.7% 
Hypertension 47% 32% 43% 33% 
Total cholesterol ≥ 240 mg/dL 13% 18% 14% 16% 
LDL ≥ 130 mg/dL 30% 34% 32% 32% 
HDL < 40 mg/dL 6.9% 8.8% 16% 26% 
Prevalent CHD 7.8% 6.0% 7.1% 9.4% 
*Bold is to highlight the differences across groups; it does not represent a significance test. 
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Figure 2.3.  Annual rate of first heart attack by age, sex and race (ARIC :1987-2004).   
 
Source: American Heart Association Heart Disease and Stroke Statistics 2008.   
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Table 2.3.  Cohort studies that examined mediation of the adiposity-CVD relationship 
Citation Cohort Method of testing 
mediation 
Exposures Mediators Outcomes Conclusions / comments 
(Batty, 
Shipley et 
al. 2006) 
Whitehall Study 
(London-based 
male govt 
employees) 
Control for all 
mediators at once 
• BMI • Cholesterol 
• BP 
• glucose 
• diabetes 
Mortality: 
• CHD 
• Stroke 
• CVD 
• Non-CVD 
Depending on mortality type, 
attenuate but may or may not 
eliminate effect. 
(Bogers, 
Bemelmans 
et al. 2007) 
Meta-analysis of 
21 cohort 
studies 
Control for all 
mediators at once 
• BMI • Total 
cholesterol 
• SBP 
CHD Attenuated but did not 
eliminate the association of 
BMI with CHD. 
(Dyer, 
Stamler et 
al. 2004) 
Chicago Heart 
Assoc Detection 
Project in 
Industry Study 
Control for all 
mediators at once 
(though not testing as 
mediators) 
• BMI • SBP 
• total cholesterol 
• diabetes 
• CVD 
mort 
 
Attenuate but don’t eliminate, 
but mediators not tested/shown 
individually. 
(Hu, 
Tuomilehto 
et al. 2005) 
Finnish Control • BMI • SBP 
• Cholesterol 
• diabetes 
Mortality: 
• CVD 
• Cancer  
• All-cause 
SBP, cholesterol and diabetes 
together attenuate but do not 
eliminate the effect of BMI on 
total and CVD mort. 
(Huang, 
Rodreiguez 
et al. 1997) 
3741 Japanese-
American men 
from the 
Honolulu Heart 
Program - 71-93 
y of age 
Control.  Added 
individually/ 
successively. 
• BMI 
• WHR 
• waist 
• Fasting glucose 
• HDL 
CHD BMI & waist persist after 
adjustment for glucose but not 
after HDL. Association of BMI 
with CHD was not independent 
of abdominal adiposity.  WHR 
& waist circumference were 
significant after adjustment for 
BMI. 
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Citation Cohort Method of testing 
mediation 
Exposures Mediators Outcomes Conclusions / comments 
(Jousilahti, 
Tuomilehto 
et al. 1996) 
Finnish Control individually, 
but treat smoking 
individually also, so 
individual models do 
not control for 
smoking. 
• BMI • Cholesterol 
• SBP 
 
CHD 
mortality 
Men: Both attenuate but do not 
eliminate. 
Women: Cholesterol attenuates 
but does not eliminate.  SBP 
attenuates and eliminates. 
Stratified by age:  BMI effects 
were stronger in older men and 
in younger women. 
(Kanaya, 
Vittinghoff 
et al. 2003) 
Heart and 
Estrogen/ 
progestin 
Replacement 
Study (HERS) 
trial & HERS II 
cohort 
Time-dependent 
covariates in Cox 
model (using most 
recent value for the 
covariate). 
• BMI 
• waist 
• Δ in 
weight 
• Δ in waist 
• diabetes 
• HT 
• Lipids (total 
cholesterol, 
HDL, LDL, 
Lp(a)) 
Mortality: 
• Total 
• CHD 
According to the text, the 
mediators attenuated the 
association between waist and 
both outcomes, but did not 
change the inverse association 
between BMI and either 
outcome when both were in the 
model.  Diabetes was the 
principal mediator of waist for 
both outcomes.   
(Kannel, 
Wilson et 
al. 2002) 
Framingham Control & 
stratification by 
number of risk factors 
(including age & 
smoking as well as 
BP, cholesterol, 
diabetes) 
• BMI • HDL 
• Total 
cholesterol 
• Type 2 diabetes 
• SBP 
• heart rate 
• ECG-LVH 
• MI and 
CHD 
death 
All but heart rate and 
overweight were significant in 
the final model.  Overweight 
was still a substantial predictor 
of CHD in men, and obesity 
was significant and substantial 
in both genders. 
(Kim, 
Meade et 
al. 2006) 
Northwick Park 
heart 
Control – Mediators 
added successively to 
model, so not tested 
independently 
• Skinfolds 
• BMI 
• BP 
• Cholesterol 
• Fibrinogen 
• Factor VII 
• CHD 
mortality 
• Total 
mortality 
The effect of obesity on CHD 
mortality was not mediated by 
BP, cholesterol, fibrin, or 
factor VII. 
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Citation Cohort Method of testing 
mediation 
Exposures Mediators Outcomes Conclusions / comments 
(Mann, Lee 
et al. 2006) 
NHANES I 
Epidemiologic 
Follow-up 
Control and 
stratification 
• BMI • HT 
• total chol 
• diabetes 
(stratified) 
• CHD 
mort 
Compared to lean non-
diabetics, OW & OB diabs and 
OB non-diabs have 
significantly higher HR 
(Manson, 
Colditz et 
al. 1990) 
Nurses Health Control • Current 
BMI 
• History of 
hypertension 
• History of 
diabetes 
• History of high 
cholesterol 
• Non-fatal 
MI and 
fatal CHD 
Eliminated the effect of BMI 
25 -< 29, but only attenuated 
for BMI ≥ 29 kg/m2.   
(Mora, 
Yanek et al. 
2005) 
Johns Hopkins 
Sibling Study 
(families with 
known 
premature 
CHD) 
Compared fit of 
model with 
Framingham Risk 
Score (FRS) & BMI 
to model w/o BMI. 
Tested for interaction 
between FRS & BMI. 
• BMI •  (FRS = age, 
total chol, HDL, 
BP, diabetes, 
smkg) 
CHD events They were not really trying to 
test mediation.  The best fitting 
model was the one with BMI, 
FRS and BMI*FRS.  BMI was 
an independent predictor of 
CHD events. 
(Onat, 
Uyarel et 
al. 2006) 
Turkish Adult 
Risk Factor 
Study 
Control • Waist • Cholesterol  
(also PA and 
alcohol added at 
same time) 
incident 
CHD 
The effect of waist was 
eliminated in terms of 
significance, but the RR was 
still large. 
(Rosengren, 
Wedel et al. 
1999) 
Goteborg 
(Sweden) 
primary 
prevention trial  
Control for all 
mediators at once 
• BMI 
• Weight 
gain 
• SBP 
• Total 
cholesterol 
• Diabetes 
• Coronary 
mortality 
• Total 
mortality 
Mediators attenuated and 
almost eliminated the effect of 
BMI.  They attenuated but did 
not eliminate eliminate the 
effect of weight gain. 
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Citation Cohort Method of testing 
mediation 
Exposures Mediators Outcomes Conclusions / comments 
(Song and 
Sung 2001) 
Korean Civil 
Servants (males) 
Control for all 
mediators at once 
BMI  • DBP 
• Total 
cholesterol 
• Glucose 
Mortality: 
• All-cause 
• Coronary 
• Cancer 
• Cerebro-
vascular 
• The rest 
The mediators attenuated but 
did not eliminate the effect of 
BMI for most outcomes.  
(Weight was not measured 
using one standard, though 
measures were done at a 
doctor’s office) 
(Tanne, 
Medalie et 
al. 2005) 
Israeli Ischemic 
Heart Disease 
Control • BMI 
• Sum of 
skinfolds 
• Skinfold 
ratio 
• BP 
• diabetes 
• Stroke 
mortality 
• CHD 
mort 
SBP alone attenuated and 
statistically eliminated the 
effects of adiposity, but the 
other mediators were not 
tested/shown individually. 
(Zoppini, 
Verlato et 
al. 2003) 
Verona Diabetes 
Study 
Control for all 
mediators at once 
BMI • Duration of 
diabetes 
• Fasting glucose 
• Hypertension 
Mortality: 
• All-cause 
• CVD 
• Malig-
nancies 
The mediators attenuated what 
were mostly non-significant 
risks in those < 65 years.  For 
those ≥ 65, BMI was non-
significantly protective. 
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Table 2.4.  Comparison of beta coefficients for body mass index and waist 
circumference from same time (cross-sectional) and three-year lag (longitudinal) 
analyses 
 Body Mass Index  Waist Circumference 
 ΒBMI 95% CI 
Wald p-
value*  ΒWC 95% CI 
Wald 
p-
value* 
Systolic blood pressure       
   Same time 0.46 (0.41,0.50)   0.15 (0.13,0.16)  
   Three-year lag 0.41 (0.36,0.47) .1149  0.15 (0.13,0.16) .9293 
Diastolic blood pressure       
   Same time 0.22 (0.19,0.25)   0.07 (0.06,0.08)  
   Three-year lag 0.12 (0.09,0.15) <.0001  0.04 (0.03,0.05) <.0001 
Glucose        
   Same time 0.47 (0.44,0.50)   0.15 (0.14,0.17)  
   Three-year lag 0.43 (0.40,0.47) .0208  0.16 (0.14,0.17) .8271 
Total cholesterol       
   Same time 0.43 (0.31,0.54)   0.19 (0.15,0.23)  
   Three-year lag -0.11 (-0.22,0.01) <.0001  -0.01 (-0.05,0.03) <.0001 
HDL cholesterol       
   Same time -0.90 (-0.94,-0.85)   -0.29 (-0.31,-0.28)  
   Three-year lag -0.77 (-0.82,-0.73) <.0001  -0.28 (-0.30,-0.27) .2259 
LDL cholesterol       
   Same time 0.56 (0.45,0.67)   0.21 (0.17,0.25)  
   Three-year lag 0.16 (0.05,0.27) <.0001  0.08 (0.04,0.11) <.0001 
Triglycerides        
   Same time 3.93 (3.69,4.18)   1.43 (1.35,1.52)  
   Three-year lag 2.90 (2.64,3.16) <.0001  1.11 (1.02,1.21) <.0001 
*Testing whether the longitudinal estimate differs from the cross-sectional estimate 
 
 
 
  
III. METHODS  
A. The ARIC Study data 
The ARIC study is a prospective, multi-site investigation of atherosclerosis and 
cardiovascular disease (ARIC Investigators 1989).  Baseline data were collected from 1987-
1989 in 15,792 African American and White men and women, 45-64 years of age.  Races 
other than African American or White (n=48) and African Americans in Minneapolis and 
Washington County (n= 55) were excluded per standard ARIC protocol because their 
numbers are too small to allow ethnic and field-center specific analyses, leaving 15,689 
participants.  These participants were from four communities in the United States:  Forsyth 
County, NC (12% African American; 88% White); Jackson, MS (100% African American); 
the northwestern suburbs of Minneapolis, MN (100% White); and Washington County, MD 
(100% White).  A range of physiologic and behavioral risk factors were measured.  
Participants were measured in a maximum of four clinic visits at approximately three year 
intervals (Table 3.1).  The ARIC study uses a combination of cohort and community 
surveillance for the ascertainment and validation of cardiovascular events and vital status.  
Currently less than 1% of the ARIC cohort is lost to follow-up.  Data were available through 
December 31st, 2005 for this analysis.  
1. Variables 
a. 
Height was measured in visits 1, 3 and 4. Weight was measured at all 4 visits.  Height 
was measured to the nearest centimeter using a metal rule attached to a wall and a standard 
Height and weight 
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triangular head board.  Weight was measured to the nearest pound using a beam balance with 
subjects in a scrub suit and no shoes.   
b. 
Incident CHD is defined as cardiac death, non-fatal MI, silent MI or cardiovascular 
surgery or coronary angioplasty.  To identify events, interviewers contacted participants’ 
homes annually to obtain information on all hospitalizations and deaths.  ARIC staff also 
surveyed discharge lists from local hospitals and local obituaries and conducted an annual 
review of vital statistics tapes.  Death certificates were obtained for all deaths.  Trained 
abstractors obtained hospital charts and recorded the presenting signs and symptoms.  To 
detect incident CHD, abstracted information included chest pain, cardiac enzymes, and 
related clinical information (White, Folsom et al. 1996).  Up to three 12-lead 
electrocardiograms were photocopied and sent to the University of Minnesota where they 
were visually coded (Prineas, Harland et al. 1982).  Out of hospital deaths were investigated 
using interviews with the next of kin (in approximately 81% of cases) and questionnaires 
completed by the patients’ physicians (in approximately 91% of cases).  Two members of the 
ARIC Morbidity and Mortality Classification Committee reviewed all potential clinical CHD 
events, and the chair of the Committee adjudicated differences between the two reviewers.  
Unrecognized MI was defined by a major Q wave or a minor Q wave with ischemic ST-T 
changes in the first and subsequent ARIC examinations or by computerized NOVACODE 
(Rautaharju, Warren et al. 1981) criteria, confirmed by side-by-side ECG comparison. 
CHD 
Collection of data on events in the ARIC cohort is on-going.  Closure of incident 
CHD files lags real time by at least one year.  We had 16-19 years of follow-up available for 
this analysis (from entry in 1987-89 through December, 2005).  Both occurrence and date of 
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event were available.  For all hazard analyses, time to event was defined as time from the 
subject’s baseline visit to the event date or to the censored date (12/31/05). 
c. 
Systolic and diastolic blood pressures were measured three times after a 5-minute rest 
using a random zero sphygmomanometer on the right arm of the seated participant.  The last 
two measures were averaged and recorded.  Study participants were asked to fast for 12 
hours prior to their clinic visit and fasting blood samples were sent to the ARIC Central 
laboratories.  Total plasma cholesterol (Siedel, Hagele et al. 1983) and triglycerides (Nagele, 
Hagele et al. 1984) were determined by enzymatic methods.  HDL cholesterol was measured 
after dextran-magnesium precipitation (Warnick, Benderson et al. 1982).  Serum glucose 
levels were measured by a hexokinase/ glucose-6-phosphate dehydrogenase method and 
insulin by radioimmunoassay (125Insulin Kit; Cambridge Medical Diagnostics, Inc., Billerica, 
MA).  Insulin resistance was calculated using the Homeostatic Model Assessment equation 
(plasma glucose (mmol/l) times serum insulin (mU/l) divided by 22.5) (Bonora, Targher et 
al. 2000).  We considered using the spreadsheet macro which employs the algorithm that the 
equation is supposed to approximate (Wallace, Levy et al. 2004).  However, at high values of 
glucose and insulin, we found the macro to be highly unstable and the resulting values for 
insulin resistance were less correlated with our other variables than were the values 
calculated using the equation.   
Physiologic risk factors  
d. 
Medication records were collected at each clinic visit. Participants were reminded to 
bring all medications used in the previous two weeks.  Names of the medications were 
transcribed and coded by the ARIC medication coding system, developed by a pharmacist at 
Medication use 
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UNC.  The ARIC medication codes were then mapped to Medi-Span Therapeutic 
Classification (MTC) codes and American Hospital formulary Service Classification 
Compilation (AHFSCC) codes.  Subjects were classified as taking medications for blood 
pressure or lipids if they self-reported taking medications in general in the last two weeks, 
and the medications they brought included an appropriately classified medication.  Use of 
glucose-lowering medications is based on self-report of taking medications for diabetes or 
high blood sugar in the past 2 weeks.  
e. 
Age (date of birth), race/ethnicity, and gender were self-reported.  Additional 
covariates were assessed by interviewer-administered questionnaires.  We categorized 
education as less than a high school education, high school graduate, or at least some college.  
Physical activity was assessed with the Baecke leisure time physical activity questionnaire 
(Baecke, Burema et al. 1982) and categorized in tertiles.  Self-reported cigarette smoking 
status and alcoholic beverage consumption were categorized as current, former, or never.  
Participants were asked about a number of possible sources of health insurance, categorized 
for this analysis as insured or uninsured.  Participants were also asked if either parent had a 
history of myocardial infarction, which we categorized as yes if either parent did and no if no 
parent did.  Family history of high blood pressure and of diabetes were coded in the same 
way.  A race-field center variable was created because all field centers did not have both race 
groups.  
Covariates 
2. Quality control 
ARIC field centers used a computer-assisted data collection system in which staff 
directly recorded the information collected from interviews and examinations.  Rigorous 
  32 
quality control procedures were developed and implemented for all parts of the examination 
to ensure that data were collected uniformly at each center and over time.  The Collaborative 
Studies Coordinating Center at UNC-Chapel Hill served as the study coordinating center.  
Several papers evaluating quality control in the ARIC study have been published 
(Chambless, McMahon et al. 1992; Chambless, McMahon et al. 1992; Chambless, McMahon 
et al. 1993; Ma, Folsom et al. 1995; Sorlie, Cooper et al. 1996; Stevens, Metcalf et al. 1996; 
Coady, Sorlie et al. 2001; Schroeder, Whitsel et al. 2004). 
B. Analytic methods 
Methods used in individual papers are summarized in those chapters.  Here I present 
additional detail about methods used and considered.   
1. Mediation 
The regression-based approach to assessing mediation seen most often in the 
epidemiologic literature simply runs two regressions – one without a proposed mediator and 
one with the mediator, e.g.: 
Model 1:  Outcome = Main exposure  
Model 2:  Outcome = Main exposure + mediator 
If the mediator is significant in model 2, mediation is assumed to occur.  If the main 
exposure is no longer significant in model 2, then the mediator is considered to fully mediate 
the relationship between the main exposure and the outcome.  If the main exposure is still 
significant, mediation is assumed to be partial. 
In 1986, Baron and Kenny proposed an alternative modeling approach, using three 
regression equations (Figure 3.1):   
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Model 1 (Step 1):  Outcome = Main exposure 
Model 2 (Step 2):  Mediator = Main exposure 
Model 3 (Steps 3 and 4):  Outcome = Main exposure + mediator 
With this approach, the product of a x b equals the indirect effect, and is equivalent to 
c-c’.  The advantage of this approach is that a standard error can be calculated for a x b, and 
the significance of the indirect effect can be tested.  More recently, methods for testing 
indirect effects in small samples and with non-linear models have been developed, including 
bootstrapping (Shrout and Bolger 2002; MacKinnon, Fairchild et al. 2007). 
2. Structural equation modeling 
SEM uses variance and covariance matrices to test relationships among all specified 
paths in a model at once (e.g., Figure 3.2).  It returns values (standardized and 
unstandardized) for all paths as well as measures of overall model fit (variance in the 
outcome explained by the model).  Path coefficients represent change in the dependent 
variable associated with a 1-unit change in the independent variable (the same as in 
regression).    
SEM has several advantages over standard regression.  It allows the researcher to 
specify paths among the variables in the model and to leave out paths where a relationship is 
hypothesized not to exist.  It does not assume that independent variables are measured 
without error, but instead can explicitly model that error.  We had hoped to take advantage of 
this feature, as the ARIC study has reliability data on the exposure and mediators of interest 
for this study, but were not able to do so (see “Additional methodologies considered”, 
below).  SEM permits comparison of model fit and significance of the indirect effect across 
race-gender groups.  The use of a time-to-event outcome in SEM is a recent technique, and as 
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such has not been implemented often, especially using continuous survival data.  However, a 
few papers on the methods exist (Larsen 2004; Larsen 2005; Asparouhov 2006), and there 
are at least two examples of usage in health literature (Moustaki and Steele 2005; Christ, Lee 
et al. 2008).   
a. 
All mediation analyses used Mplus statistical software.  Mplus is a software package 
that can be used for a variety of analyses, including linear and logistic regression, multi-level 
modeling, survival analysis, factor analysis and structural equation modeling.   
SEM Software 
3. The delta method 
The delta method was used in Mplus to calculate standard errors for indirect effects.  
The delta method is a technique for calculating the variance around some function of an 
estimate by estimating a linear approximation of the function and calculating the variance of 
that function (Xu 2005).  As long as the function satisfies certain requirements, such as being 
differentiable, the delta method can be used (Greene 2003).  It is appropriate for linear and 
non-linear combinations of parameters.   
The mixed model analysis of stacked data presented in the secondary aim used an 
unstructured correlation matrix selected based on fit indices for several possible final models 
with both SBP and DBP as the outcome.   
4. Additional methodologies considered 
SEM does not assume that independent variables are measured without error, but 
instead can explicitly model that error.  Where measurement error has been estimated, as for 
several variables in the ARIC study, those values can be entered.  Measurement errors for 
relevant variables in ARIC are shown in Table 3.2.  We had hoped to incorporate these errors 
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into the model as shown in Figure 3.2 (example for lipids), but the models did not converge 
with error terms incorporated, so we were unable to take advantage of that aspect of SEM.  
Fortunately, reliability for the main variables of interest is high. 
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Table 3.1. Number of ARIC participants by race-gender and clinic visit 
 African 
American 
women 
White 
women 
African 
American 
men 
White 
men 
Totals 
Visit 1 (1987-1989) 2,609 6,050 1,602 5,428 15,689 
Visit 2 (1990-1992) 2,225 5,675 1,303 5,054 14,257 
Visit 3 (1993-1995) 1,883 5,249 1,072 4,603 12,807 
Visit 4 (1996-1998) 1,686 4,792 940 4,169 11,587 
Completed all 
 
1,520 4,657 824 4,070 11,061 
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X c Y 
X c’ Y 
a 
M 
b 
c = total effect 
c’ = direct effect 
Step 1 
Step 2 Step 3 
Step 4 
Figure 3.1:  Baron and Kenny Mediation 
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Table 3.2.  Reliability coefficients (R) for key variables 
BMI  
(Klipstein-
Grobusch, 
Georg et al. 
1997) 
TC  
(Chambless
, McMahon 
et al. 1992) 
HDL 
(Chambless
, McMahon 
et al. 1992) 
TG 
(Chambless
, McMahon 
et al. 1992) 
Glucose 
(Eckfeldt, 
Chambless 
et al. 1994) 
SBP 
(Weatherley
, Chambless 
et al. 2006) 
.99 .94 .94 .85 .84 .74 
*An R of 1.0 reflects perfect reliability 
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η=latent endogenous variable;  ζ=latent error term;  y=observed endogenous variable;  ε= observed error term;  ξ=latent 
exogenous variable;  x=observed exogenous variable;  δ=disturbance term;  φ=covariance of exogenous variables;  
λ=factor loading;  γ=path coefficient for association of an endogenous variable with an exogenous variable;  β=path 
coefficient for association of an endogenous variable with another endogenous variable 
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Figure 3.2: Structural equation model with variables modeled as single-indicator latent variables 
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IV. MEDIATION OF EFFECTS OF BODY MASS INDEX ON CORONARY HEART DISEASE BY 
ESTABLISHED PHYSIOLOGIC RISK FACTORS IN A BI-ETHNIC COHORT: THE 
ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY 
A. Abstract 
We used structural equation models to determine whether established physiologic risk 
factors mediated the association between body mass index (BMI) and coronary heart disease 
(CHD) and whether mediation differed by race or gender.  The Atherosclerosis Risk in 
Communities (ARIC) Study is a cohort of African American and White adults aged 45-64 
years at baseline (1987-1989), followed through 2005.  Mediators examined were total and 
HDL cholesterol (TC, HDL), triglycerides, systolic and diastolic blood pressure (SBP, DBP) 
and insulin resistance.  Participants with prevalent CHD, who had not fasted, or were missing 
variables were excluded, leaving a final sample of 13,721.  The indirect (mediated) effect of 
BMI on CHD through each mediator was calculated as the predicted hazard ratio associated 
with the change in the risk factor predicted by 3 specific contrasts of BMI: 25 vs. 20 kg/m2, 
30 vs. 25 kg/m2 and 35 vs. 30 kg/m2.  The effect of BMI on CHD was curved, with a steeper
slope between a BMI of 20 and 25 kg/m2 than between 30 and 35 kg/m2.  In the model 
without mediators, hazard ratios (HRs) and 95% confidence intervals for the effect of BMI 
on CHD were 1.39 (1.26,1.54) for the 25 vs. 20 kg/m2 contrast and 1.20 (1.15,1.26) for 35 vs. 
30 kg/m2.  In models that included all 6 hypothesized mediators, BMI was not directly 
associated with CHD.  Mediated effects of BMI on CHD tended to be strongest through HDL 
cholesterol (HR: 1.24 (95% CI: 1.15,1.34) for the 25 vs. 20 kg/m2 and 1.10 (1.06,1.14) for 
the 35 vs. 30 kg/m2 contrast) and through insulin resistance (1.09 (1.03, 1.16) and 1.11 (1.08, 
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1.13) for the respective contrasts).  Mediation was more moderate through total cholesterol 
(1.06 (1.04,1.07) and 1.00 (1.00,1.01), respectively) and SBP (1.06 (1.04, 1.08) and 1.05 
(1.04, 1.06), respectively), and was null through DBP and triglycerides.  We found no 
differences in mediation by race or gender.  The effect of BMI on CHD was completely 
mediated in this population by total and HDL cholesterol, SBP and insulin resistance.  The 
relative importance of these mediators varied by level of BMI. 
B. Background 
Obesity is associated with increased risk of coronary heart disease (CHD) (Folsom, 
Stevens et al. 1998; Kannel, Wilson et al. 2002; Mann, Lee et al. 2006), which is the leading 
cause of death in the United States (AHA 2007).  This association is thought to occur at least 
partly via effects on blood pressure, lipids and glucose (Ledoux, Lambert et al. 1997; Zhu, 
Heshka et al. 2004), risk factors for CHD (Folsom, Szklo et al. 1997; NCEP 2001; Lloyd-
Jones 2007).  Few studies have attempted to quantify the mediation of the obesity-CHD 
relationship by these established physiologic risk factors.  Epidemiologic analyses of 
mediation typically do not calculate indirect (mediation) effects through individual risk 
factors, but instead assess whether the direct effect of obesity is reduced after potential 
mediators are added to a model, often in one block (Rosengren, Wedel et al. 1999; Batty, 
Shipley et al. 2006; Kim, Meade et al. 2006).  This approach is limited in that indirect effects 
through individual risk factors are not calculated or compared (MacKinnon, Lockwood et al. 
2002).   
Path analysis in a structural equations model (SEM) permits the calculation of 
individual mediation paths in single- and multiple-mediator models, and allows comparisons 
across mediators.  We are not aware of any analyses of obesity and CHD that have used this 
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methodology, although it is commonly used in the social sciences to quantify and compare 
indirect effects.  Further, we know of no studies that have addressed racial differences in the 
mediation of obesity’s effects on CHD using any methodology.  Racial differences have been 
found in the prevalences of obesity (Li, Ford et al. 2007; Ogden 2007), CHD risk factors 
(Winkleby, Kraemer et al. 1998; Sundquist, Winkleby et al. 2001) and CHD outcomes 
(Clark, Ferdinand et al. 2001; Jones, Chambless et al. 2002; American Heart Association 
2008), as well as in the associations among these variables (Despres, Couillard et al. 2000; 
Harris, Stevens et al. 2000; Jones, Chambless et al. 2002; Carnethon, Lynch et al. 2006; Shai, 
Jiang et al. 2006; Abell, Egan et al. 2008), so differences in mediation might be expected.    
The objective of this analysis was to quantify the direct and indirect effects of body 
mass index (BMI) on CHD through established physiologic risk factors and to compare the 
relative strength of the mediators.  The risk factors examined were total and high-density 
lipoprotein (HDL) cholesterol, triglycerides, systolic and diastolic blood pressure, and insulin 
resistance.  We also compared mediation across race (African American and White) and 
gender groups.    
C. Methods 
1. Study population 
The Atherosclerosis Risk in Communities (ARIC) Study is a prospective 
investigation of atherosclerosis and cardiovascular disease in a cohort of 15,792 African 
American and White adults aged 45-64 years at baseline (1987-1989).  Participants were 
from four communities in the United States: Forsyth County, NC, Jackson, MS, Minneapolis, 
MN, and Washington County, MD.  Participants were examined at four study visits spaced 
approximately 3 years apart.  Details of the study design have been described previously 
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(ARIC Investigators 1989).  Races other than African American or White (n=48) and African 
Americans in Minneapolis and Washington County (n= 55) were excluded per standard 
ARIC protocol because their numbers are too small to allow ethnic and field-center specific 
analyses.  This study was approved by the Institutional Review Board (IRB) at each field 
center, and this analysis was approved by the University of North Carolina Public Health-
Nursing IRB on research involving human subjects.    
2. Measurements 
Body weight was measured at all clinic visits in a scrub suit to the nearest pound by 
use of a beam balance scale.  Standing height (without shoes) was measured to the nearest 
centimeter using a metal rule and a standard triangular headboard.  BMI was calculated as 
weight in kilograms divided by height in meters squared.  Systolic and diastolic blood 
pressures were measured three times after a 5-minute rest using a random zero 
sphygmomanometer on the right arm of the seated participant.  The last two measures were 
averaged and recorded.  Participants were asked to fast for 12 hours prior to clinic visit.  
Serum glucose levels were measured by a hexokinase/ glucose-6-phosphate dehydrogenase 
method and insulin by radioimmunoassay (125Insulin Kit; Cambridge Medical Diagnostics, 
Inc., Billerica, MA).  Insulin resistance was calculated using the Homeostatic Model 
Assessment equation (plasma glucose (mmol/l) times serum insulin (mU/l) divided by 22.5) 
(Bonora, Targher et al. 2000), and was log-transformed for analysis.  Total plasma 
cholesterol (Siedel, Hagele et al. 1983) and triglycerides (Nagele, Hagele et al. 1984) were 
determined by enzymatic methods.  Triglycerides were also log-transformed for analysis.  
HDL cholesterol was measured after dextran-magnesium precipitation (Warnick, Benderson 
et al. 1982). 
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Coronary heart disease is defined as: cardiac death, non-fatal myocardial infarction 
(MI), silent MI detected by echocardiogram (ECG), or cardiovascular surgery or coronary 
angioplasty (White, Folsom et al. 1996).  Follow-up of CHD events was available through 
December 31st, 2005.  For all hazard analyses, time to event was defined as time from the 
subject’s baseline visit to the event date or censored date.  Prevalent CHD at baseline was 
defined for exclusion in these analyses as a reported history of a physician-diagnosed MI, MI 
detected by ECG, or cardiovascular surgery or coronary angioplasty.  Age (date of birth), 
race/ethnicity, and gender were self-reported.  Additional covariates were assessed by 
interviewer-administered questionnaires.  We categorized education as less than a high 
school education, high school graduate, or at least some college.  Physical activity was 
assessed with the Baecke leisure time physical activity questionnaire (Baecke, Burema et al. 
1982) and categorized in tertiles.  Self-reported cigarette smoking status and alcoholic 
beverage consumption were categorized as current, former, or never.  Participants were asked 
about a number of possible sources of health insurance, categorized for this analysis as 
insured or uninsured.  Participants were also asked if either parent had a history of 
myocardial infarction, which we categorized as yes if either parent did and no if no parent 
did.  Family history of high blood pressure and of diabetes were coded in the same way.  A 
race-field center variable was created because all field centers did not have both race groups.  
3. Statistical analyses 
We excluded persons with prevalent or missing CHD at baseline (n=1,102) and 
participants who had not fasted at least 8 hours (n=515), as well as participants missing BMI 
(n=22), systolic or diastolic blood pressure (n=4), lipids (n=188), glucose or insulin (n=9) or 
covariates (n=128).  The final sample size was 13,721, comprising 5,635 White women, 
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2,147 African American women, 4,650 White men and 1,289 African American men.  Mean 
follow-up time was 15.2 years. 
We used structural equation models in conjunction with Cox proportional hazards 
regression in Mplus 5.0 to assess the indirect effect of baseline BMI on time to CHD through 
each of the physiologic risk factors, as well as the direct effect of BMI on CHD.  BMI and all 
of the risk factors were analyzed as continuous variables.  Risk factors were examined as 
mediators in separate models and in a combined model with all risk factors together.     
The conceptual model for the mediation analysis is illustrated in Figure 4.1.  
Structural equation models incorporate several regression equations simultaneously to obtain 
path coefficients for each relationship.  Linear regression was used to examine the 
relationship between BMI and physiologic risk factors (path A), and Cox proportional 
hazards regression was used to examine the relationships between risk factors and CHD (path 
B) and between BMI and CHD (path C’, the direct effect).  The total effect (path C, not 
shown) is the association of BMI with CHD in a proportional hazards model with no 
mediators in the model.  
We examined quadratic terms and interactions for BMI and mediator variables.  We 
kept quadratic terms that resulted in nonlinear estimates.  Final equations for all paths are 
shown in Table 4.1.  A quadratic relationship was found for the association of BMI with each 
risk factor and with CHD, so the BMI-risk factor (path A) associations and the total and 
direct effects of BMI (paths C and C’) were predicted and reported for 3 specific contrasts of 
BMI: 25 vs. 20, 30 vs. 25 and 35 vs. 30 kg/m2.  Quadratic associations of risk factors with 
CHD were observed for total cholesterol, triglycerides, diastolic blood pressure and insulin 
resistance.  We therefore calculated hazard ratios for 2 specific contrasts of each risk factor: 
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the mean plus one standard deviation vs. the mean, and the mean vs. the mean minus one 
standard deviation.  Interactions with BMI were observed for associations of HDL-
cholesterol, triglycerides and diastolic blood pressure with CHD in individual-mediator 
models, but did not affect estimates in the combined mediator model and so were dropped 
from all models in favor of parsimony and simplicity of presentation of results.   
The indirect (mediated) effect is the change in the outcome variable associated with 
the change in the mediator estimated for a given change in the exposure variable.  In models 
without quadratic terms, the indirect effect is calculated by multiplying the path coefficients 
from the BMI-risk factor (path A) and the risk factor-CHD (path B) (Bollen 1989), where A 
is the change in the mediator for each 1-unit increment in exposure, and B is the change in 
the log hazard ratio (HR) of the outcome per 1-unit increment in the mediator.  Because of 
the non-linear associations in our models, we calculated indirect effects by predicting the 
value of each risk factor for a BMI of 20, 25, 30 and 35 kg/m2, using mean values of 
covariates, and then estimating the log CHD hazard ratios associated with the contrast 
between the predicted risk factor values.  We report the indirect (mediated) hazard ratio, 
which was the exponentiated change in the log CHD hazard ratio for each of these 5-unit 
increments in BMI.  Standard errors for the indirect hazard ratios were calculated using the 
delta method.     
All mediation models were adjusted a priori for age (centered), gender, race, field 
center, smoking, alcohol use, physical activity, education and insurance status.  An age-
squared term was also included in all of the models because age effects were curved in some 
of them.  Family history of myocardial infarction, diabetes or hypertension was also included 
in portions of the model with relevant outcomes.  Total calories and sodium intake were also 
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considered as covariates, but were not significant predictors of the outcome variables and did 
not change the main effects.  Analyses were stratified by race-gender groups, and differences 
in A paths, B paths and indirect effects across groups were assessed using a Wald test.    
D. Results 
Sample characteristics at baseline are shown in Table 4.2 by BMI categories.  Obese 
individuals were disproportionately African American women.  Obese individuals had higher 
mean levels of all of the risk factors.  They were less educated and less likely to have health 
insurance, less likely to be current drinkers or smokers and more likely to be former drinkers 
or smokers.  Obese participants were less likely to be in the highest and more likely to be in 
the lowest tertile of leisure activity and were more likely to have a family history of diabetes 
or hypertension.  Overweight and obese persons had a higher unadjusted incidence of CHD 
events than leaner individuals.  
Table 4.3 shows the predicted effects of BMI on physiologic risk factors (A paths) for 
the 3 BMI contrasts.  BMI was a strong predictor of all of the risk factors examined.  The 
associations became weaker at higher BMI levels for all of the risk factors, especially total 
cholesterol.    
Hazard ratios for the effect of standard deviation contrasts of physiologic risk factors 
on CHD are shown in Table 4.4 for single-mediator models and for the model with all 
mediators together.  Each risk factor was significantly associated with CHD in single-
mediator models.  In the multiple-mediator model, triglylcerides no longer predicted CHD.  
Diastolic blood pressure was null for the contrast above the mean, but weakly protective 
below.  The association with insulin resistance was somewhat reduced.  There was little 
difference between the single-mediator and multiple-mediator models for other risk factors.      
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Total and direct effects of BMI on CHD (C and C’ paths) are shown in Table 4.5.  
BMI was associated with CHD in the model without mediators (C-path HRs for 5-unit 
contrasts of BMI range from 1.20 to 1.39).  The addition of single mediators generally 
attenuated, but did not eliminate the effect of BMI on CHD (C’ path).  Total cholesterol had 
little effect on the BMI estimate, whereas insulin resistance substantially attenuated the direct 
effect of BMI.  BMI was no longer a direct predictor of CHD in the model with all mediators 
together.     
Table 4.6 and Figure 4.2 show the indirect (mediated) effects of the 3 contrasts of 
BMI on CHD through each mediator.  When mediators were entered individually, all of the 
confidence intervals excluded the null except for total cholesterol and diastolic blood 
pressure for the 35 vs. 30 kg/m2 contrast.  Mediation tended to be weaker at higher BMI 
levels for all risk factors except systolic blood pressure.  In the multiple-mediator model, 
indirect effects of BMI through total and HDL cholesterol, systolic blood pressure and 
insulin resistance were observed.  However, mediation by insulin resistance no longer 
weakened with increasing BMI, as it had in the single-mediator model.   
The relative strength of the mediation varied with the level of BMI.  HDL was the 
strongest mediator for the 25 vs. 20 kg/m2 contrast, with total cholesterol, systolic blood 
pressure and insulin resistance acting as lesser mediators.  Whereas for the 35 vs. 30 kg/m2 
contrast, HDL cholesterol and insulin resistance acted as similar and relatively strong 
mediators of BMI, with less mediation through systolic blood pressure and none through total 
cholesterol.   
We found few differences by race-gender groups in effects of risk factors on CHD (B 
paths) or in mediation (indirect effects), and there was no clear pattern in the few differences 
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that were seen.  Given the large number of paths tested and the modest p-values for the few 
differences found, we did not report stratified results.  We did observe some differences in 
associations of BMI with risk factors (A paths).  Compared to Whites, African American 
women had weaker associations of BMI with systolic and diastolic blood pressures, 
especially at lower BMIs.  African American women also had weaker associations of BMI 
with triglycerides than White men or women or African American men.  Associations of 
BMI with insulin resistance were stronger in men than in women, and were weakest in 
African American women, especially at higher BMIs.  None of the differences observed in 
the A paths persisted in the indirect effects.    
E. Discussion 
Consistent with other longitudinal studies (Jousilahti, Tuomilehto et al. 1996; Bogers, 
Bemelmans et al. 2007), BMI predicted CHD in this analysis.  The association was 
curvilinear, with a steeper gradient at lower BMIs and a flatter slope at higher BMIs, though 
the association remained positive through the BMI range shown here.  A similar shape has 
been seen in some studies with similar baseline age and outcome definition (Rexrode, Buring 
et al. 2001; Yarnell, Patterson et al. 2001), though others have seen a linear (Manson, Colditz 
et al. 1990) or J-shaped association (Tunstall-Pedoe, Woodward et al. 1997).  It is difficult to 
compare many studies to the results observed here because BMI is commonly categorized, so 
that a flattening of the slope above the highest threshold may be obscured.   
The association of BMI with CHD has been assessed in other analyses using the 
ARIC data.  A 1998 paper examined the association of BMI quartiles with fatal and non-fatal 
coronary heart disease, excluding cardiac procedures (Folsom, Stevens et al. 1998).  A 
roughly J-shaped association was observed in men, and a more linear association was 
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observed in women.  The 11 years of additional follow-up time and use of continuous BMI in 
the present analysis could account for differences observed.  The exclusion of cardiac 
procedures does not appear to account for the differences based on the results of a sensitivity 
analysis, discussed below.  Also using ARIC data, Chambless et al. found no association 
with BMI when it was added to a baseline model based on the Framingham risk score that 
already included smoking, systolic blood pressure, total cholesterol, HDL cholesterol and 
diabetes status (Chambless, Folsom et al. 2003).  This agrees with our observation that there 
was no direct effect of BMI on CHD when all of the mediators were included in the model, 
indicating that all of the association of BMI with CHD can be accounted for by the 
physiologic risk factors we examined. 
The association between BMI and CHD observed here was mediated by total and 
HDL cholesterol, systolic blood pressure and insulin resistance.  A number of other cohort 
analyses have examined mediation of the relationship between CHD and weight-related 
variables by established physiologic risk factors using more traditional methods.  The 
majority found that the assessed mediators attenuated but did not eliminate the relationship 
between overweight and CHD (most examined fatal CHD only) (Manson, Colditz et al. 
1990; Jousilahti, Tuomilehto et al. 1996; Rosengren, Wedel et al. 1999; Song and Sung 2001; 
Kannel, Wilson et al. 2002; Dyer, Stamler et al. 2004; Hu, Tuomilehto et al. 2005), including 
a meta-analysis of 21 cohort studies (Bogers, Bemelmans et al. 2007) that found a relative 
risk for a 5-unit change in BMI of 1.27 (95% CI: 1.21, 1.33) without and 1.15 (95% CI: 1.11, 
1.19) with BP and cholesterol in the model.  A minority of studies found that the mediators 
eliminated the association with CHD (Jousilahti, Tuomilehto et al. 1996; Huang, Rodreiguez 
et al. 1997; Tanne, Medalie et al. 2005), in that the confidence interval for the obesity 
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variable included the null, but the absolute reduction in the effect was often similar to the 
other studies.  Rarely, the hypothesized mediators had no attenuating effect (Kim, Meade et 
al. 2006).  Since mediators were generally added as a group or successively, it is difficult to 
conclude from these studies which mediators were more important.    
The few studies that tested mediators individually were inconsistent.  Kim et al.(Kim, 
Meade et al. 2006) assessed BMI as a predictor of fatal CHD in the Northwick Park Heart 
Study.  The addition of cholesterol strengthened rather than attenuated the relative risk of 
BMI, but the further addition of SBP attenuated the effect.  Jousilahti et al.(Jousilahti, 
Tuomilehto et al. 1996) examined the relationship between BMI and CHD mortality in 
Finnish men and women aged 30-59.  Although total cholesterol was significant in a model 
with BMI, the addition of cholesterol did not attenuate the relationship between BMI and 
CHD mortality.  The addition of blood pressure did attenuate (and inconsistently reduced to 
null, depending on gender and age group) the relative risk for BMI.  Tanne et al (Tanne, 
Medalie et al. 2005) assessed hazard ratios for CHD in male Israeli civil servants.  The 
addition of SBP to a model with BMI and age attenuated the HR for the effect of BMI on 
CHD, whereas the further addition of diabetes, smoking and socioeconomic status produced 
little change.  None of the studies we found compared mediation in African Americans 
versus Whites. 
Mediation in the present analysis occurred through the same physiologic risk factors 
identified in several risk scores developed in other cohorts, such as the Framingham Risk 
Score (D'Agostino, Vasan et al. 2008), SCORE (Conroy, Pyorala et al. 2003), ASSIGN 
(Woodward, Brindle et al. 2007) and QRISK (Hippisley-Cox, Coupland et al. 2007), all of 
which emphasize total and HDL cholesterol, SBP and diabetes in addition to non-physiologic 
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risk factors such as smoking.  The Framingham risk score has been validated in the ARIC 
data (D'Agostino, Grundy et al. 2001).  The ARIC cohort has also been used to develop the 
Personal HEART score (Mainous, Koopman et al. 2007) based on self-reported rather than 
measured risk factors (e.g., self-reported history of high cholesterol).  This score compared 
favorably with Framingham and SCORE.  The Personal HEART score included BMI in the 
risk prediction for women, but most scores based on measured physiologic risk factors do not 
explicitly include BMI because it was no longer statistically significant once other risk 
factors were entered into the model (Woodward, Brindle et al. 2007; D'Agostino, Vasan et al. 
2008), a finding also seen here.  Nevertheless, the indirect effects reported here indicate that 
BMI is an important driver of the risk factors included in these scores.   
To our knowledge, this study is the first to show that the relative strength of the 
indirect (mediated) effects varied with the level of BMI.  Mediation through lipids weakened 
as BMI rose, whereas effects through insulin resistance and blood pressure remained similar.  
At lower BMI levels, most of the effect of BMI on CHD was mediated by HDL cholesterol.  
This suggests that the increase in CHD risk associated with higher BMI among normal 
weight individuals may be primarily due to HDL cholesterol, which drops sharply with 
increasing BMI below the threshold of obesity (BMI = 30 kg/m2) and then changes very little 
above the threshold (Table 4.1).  It also underscores the gradient of risk that exists within the 
normal weight category, a phenomenon that has received strong attention in Asians, but is 
less appreciated in Caucasians and African Americans (Stevens 2003).  HDL cholesterol is 
known to be an important risk factor for CHD, and is included in most CHD risk scores, but 
its observed impact may be diminished in cohorts dominated by overweight subjects due to 
the increased relative effects of systolic blood pressure and insulin resistance at higher BMIs.   
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We chose not to control for use of antihypertensive, anti-hyperlipidemic or diabetic 
medications.  Exclusion, stratification and adjustment for medication use have all been 
shown to bias results (Tobin, Sheehan et al. 2005) because medication use in observational 
data is so profoundly confounded by indication that the medication use variable acts as a 
marker for the risk factor itself.  As a result, statistical adjustment for medication use will 
usually bias estimates for the effect of BMI on risk factors towards the null (Schisterman, 
Cole et al. 2009), which it does in these (data not shown) and other data (Tobin, Sheehan et 
al. 2005).   Imputation is considered to be an appropriate solution for handling medication 
when the risk factor is the outcome variable, and various methods have been proposed (Cook 
1997).  However, for mediation, imputation would not have been not optimal because we 
were not only interested in the treated risk factors as outcomes (A paths), but also as 
exposures for CHD (B paths).  In the latter case, we wished to estimate effects for the actual 
experienced (treated) value of the risk factor, and we did not wish to assign different values 
of the risk factor for path A and path B. 
We conducted several sensitivity analyses to confirm our decision: 1) imputing 
treated values of the risk factors, 2) adjusting for medication use, and 3) excluding 
participants taking antihypertensive, antihyperlipidemic or diabetes medications (final 
N=9,399).  Hazard ratios for indirect effects changed very little for all analyses, differing by 
no more than 0.02 from original estimates for all mediators except insulin resistance in the 
adjusted and exclusion analyses.  We also repeated the analysis excluding cardiac procedures 
because of concerns about bias due to race, gender and other sociodemographic differences 
in use of these procedures (Lee, Folsom et al. 2001).  We found only very slight differences 
in the overall population and minor differences by race and sex that did not change our 
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conclusions or our decision to present overall rather than race and/or gender-specific results.  
Our analysis adjusted for insurance and education, as well as race and gender, which may 
explain why our results changed little despite known differences in use of procedures.   
We found few differences by race or gender in the relationships examined here.  
Effects of BMI on risk factors (A paths) initially appeared to be quite different in African 
American women compared to the other three race-gender groups, but addition of the 
quadratic BMI term reduced and/or eliminated the differences.  Racial differences have been 
observed in the association of BMI with risk factors (Colin Bell, Adair et al. 2002) and of 
both BMI (Abell, Egan et al. 2008) and physiologic risk factors (Carnethon, Lynch et al. 
2006; Shai, Jiang et al. 2006) with CHD in other large cohorts.  However, observed racial 
differences in multifactorial conditions like obesity and heart disease, or in associations 
among such conditions, are particularly subject to unmeasured confounding (Kaufman 2008).  
While it is important to describe differences observed, care should be taken with etiologic 
inference. 
The indirect HRs reported here were not large even though they are reported per 5 
units of BMI, which represent about 30 lbs for a 5’6” person, a clinically large increment.  
Five BMI units is approximately the standard deviation in this population and is also the 
difference between commonly used cutpoints for overweight (BMI = 25  kg/m2) and obese 
(BMI = 30 kg/m2).  This increment is comparable to gains seen in U.S. adults over 15-30 
years (Stevens, Tyroler et al. 1998; Gordon-Larsen, Hou et al. 2009).  Given that two thirds 
of the US population is overweight (Ogden, Carroll et al. 2006), the 5-10% increased hazards 
observed through most of the mediators for this size increment represent a large number of 
individuals at increased risk for CHD through each mediator. 
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This study had several strengths, including carefully measured CHD endpoints over a 
long follow-up period, high reliability of BMI (Klipstein-Grobusch, Georg et al. 1997) and 
physiologic risk factor measures (Chambless, McMahon et al. 1992) (Eckfeldt, Chambless et 
al. 1994) (Weatherley, Chambless et al. 2006), and a large bi-ethnic cohort, permitting 
comparisons by racial group.  The use of path analysis in structural equations models allowed 
us to quantify and compare individual indirect effects, and the use of a Cox proportional 
hazards model in SEM is relatively novel (MacKinnon, Lockwood et al. 2002; Christ, Lee et 
al. 2008).  
There are inherent limitations in drawing causal inferences from observational data, 
and these limitations may be exacerbated in an analysis in which multiple estimated 
parameters are used to calculate an additional parameter, as we have done for the indirect 
effects.  A further limitation was the inability to fully account for medication use.  We 
reported the results of sensitivity analyses, but no known method for addressing medication 
use could have adequately addressed all the issues in an observational study design.   
The association of BMI on CHD was curvilinear in this population, with a stronger 
association at the lower BMI range and a flattening of the slope as BMI increased.  The effect 
of BMI was entirely mediated by total and HDL cholesterol, SBP and insulin resistance.  
These indirect effects did not differ by race or gender, but were observed to vary by level of 
BMI.  At lower BMIs, the indirect effect through HDL was substantially larger than for other 
mediators, but at higher BMIs, which are associated with more CHD events, HDL and 
insulin resistance were similarly important.  Excess body mass, through its effect on various 
risk factors, is an important contributor to CHD risk.  In leaner individuals, the effect of body 
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mass may occur primarily through HDL-cholesterol levels.  This study underscores the 
importance of weight control for reducing CHD risk, even among lean individuals.  
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Figure 4.1: Conceptual model for the mediation analysis.  BMI, physiologic risk factors and 
covariates were measured at baseline.  Linear regression was used to examine the 
relationship between BMI and risk factor variables (path A), and Cox proportional hazards 
regression was used to examine the relationships between risk factors and CHD (path B) and 
between BMI and CHD (path C’, the direct effect).  Path C (the total effect, not shown) is the 
path from BMI to CHD in a model with no mediator.    
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Figure 4.1: Mediation analysis paths 
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Table 4.1.  Equations used in each of the structural equation models 
  
Model Equations for A paths 
Equations for C path (without mediator) and B and C’ paths (with 
mediators) 
No mediator N/A hi(t) = λ0(t) exp ( β1BMIi + β2BMI i2 + C ) 
Models with mediators  
Total cholesterol TC = α + β1BMI + β2BMI2 + C  hi(t) = λ0(t) exp ( β1BMIi + β2BMI i2 + β3TCi + β4TC i 2 + C ) 
HDL cholesterol HDL = α + β1BMI + β2BMI2 + C hi(t) = λ0(t) exp ( β1BMIi + β2BMI i2 + β3HDLi  + C ) 
Triglycerides Ln(TG) = α + β1BMI + β2BMI2 + C hi(t) = λ0(t) exp ( β1BMIi + β2BMI i2 + β3TGi + β4TG i 2 + C ) 
Systolic Blood 
Pressure SBP = α + β1BMI + β2BMI
2 + C hi(t) = λ0(t) exp ( β1BMIi + β2BMI i2 + β3SBPi + C ) 
Diastolic Blood 
Pressure DBP = α + β1BMI + β2BMI
2 + C hi(t) = λ0(t) exp ( β1BMIi + β2BMI i2 + β3DBPi + β4DBP i 2 + C ) 
Insulin 
resistance Ln(IR) = α + β1BMI + β2BMI
2 + C hi(t) = λ0(t) exp ( β1BMIi + β2BMI i2 + β3IRi + β4IR i 2 + C ) 
   
All mediators in 
one model A paths are all of the above. 
hi(t) = λ0(t) exp ( β1BMIi + β2BMI i2 + β3TCi + β4TC i 2 + β5HDLi + β67TGi + 
β7TG i 2 + β8SBPi + β9DBPi + β10DBP i 2 + β11IRi + β12IR i 2 + C ) 
C = covariates. 
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Table 4.2.  Means (SD) and prevalences of selected sample characteristics 
 Body Mass Index (kg/m2) 
  
Variable 
<20 
(n=445) 
20-<25 
(n=4,212) 
25-<30 
(n=5,404) 
30-<35 
(n=2,480) 
≥35 
(n=1,180) 
Age (years) 54 (6) 54 (6) 54 (6) 54 (6) 53 (6) 
Total cholesterol (mg/dL) 204 (40) 211 (40) 217 (42) 219 (44) 213 (40) 
HDL cholesterol (mg/dL) 67 (21) 58 (18) 50 (16) 47 (14) 48 (14) 
Triglycerides (mg/dL) 93 (43) 108 (61) 135 (88) 152 (106) 145 (99) 
Systolic blood pressure (mmHg) 115 (19) 116 (18) 121 (18) 125 (18) 130 (19) 
Diastolic blood pressure (mmHg) 69 (11) 71 (11) 74 (11) 76 (11) 78 (11) 
Insulin resistance (mU*mmol/L2) 1.4 (2) 2.0 (7) 3.4 (8) 5.5 (11) 7.7 (14) 
Race-gender group (%)      
White women 68 55 32 34 39 
African American women 10 8 14 23 39 
White men 11 29 44 33 16 
African American men 10 8 10 11 7 
Education (%)      
< High school 20 17 22 28 33 
Finished high school 44 43 40 40 41 
Some college 36 40 38 32 26 
Alcohol use (%)      
Current drinkers 63 63 59 50 37 
Former drinkers 17 16 18 20 23 
Never drinkers 20 21 23 31 40 
Smoking status (%)      
Current smokers 47 31 24 21 15 
Former smokers 19 28 35 33 31 
Never smokers 33 40 41 46 54 
Leisure time physical activity (%)      
Highest tertile 25 33 31 23 15 
Middle tertile 41 43 43 46 44 
Lowest tertile 34 24 26 31 41 
Health insurance (% with) 90 94 92 89 83 
Family history of diabetes (%) 18 21 24 28 33 
Family history of hypertension (%) 53 51 53 56 59 
Family history of MI (%) 38 40 39 38 40 
CHD events (n (%)) 40 (9%) 438 (10%) 833 (15%) 424 (17%) 180 (15%) 
Follow-up time (person-years) 6,522 65,084 81,522 36,941 17,865 
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Table 4.3.  Predicted differences in risk factors for 5-unit contrasts of BMI, the Atherosclerosis Risk  
in Communities Study 
     BMI contrast   
  25 vs. 20 kg/m2  30 vs. 25 kg/m2  35 vs. 30 kg/m2 
  Estimate 95% CI  Estimate 95% CI  Estimate 95% CI 
Total cholesterol (mg/dL)  7.23 5.90, 8.55  3.69 2.90, 4.49  0.16 -0.55, 0.88 
HDL cholesterol (mg/dL)  -8.88 -9.44, -8.32  -6.35 -6.67, -6.03  -3.82 -4.08, -3.55 
Log triglycerides  0.25 0.23, 0.27  0.18 0.17, 0.19  0.10 0.10, 0.11 
Systolic blood pressure (mmHg)  3.87 3.32, 4.42  3.52 3.18, 3.85  3.16 2.85, 3.47 
Diastolic blood pressure (mmHg)  2.04 1.71, 2.36  1.75 1.55, 1.94  1.45 1.27, 1.64 
Log insulin resistance  0.57 0.54, 0.59  0.46 0.45, 0.47  0.36 0.34, 0.37 
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Table 4.4.  Predicted CHD hazard ratios (HRs) for standard deviation contrasts of risk factors, the Atherosclerosis Risk in 
Communities Study 
   -1SD to Mean  Mean to + 1SD 
  HR 95% CI  HR 95% CI 
Mediators entered singly       
Total Cholesterol (mean (SD) = 215 (42) mg/dL)  1.34 1.25, 1.44  1.29 1.23, 1.35 
HDL cholesterol (SD = 17 mg/dL))   0.66 0.62, 0.71    
Log triglycerides (mean (SD) = 4.7 (0.5))  1.43 1.32, 1.55  1.33 1.27, 1.40 
Systolic blood pressure (SD = 19 mmHg)  1.32 1.25, 1.38    
Diastolic blood pressure (mean (SD) = 74 (11) mmHg)  1.10 1.02, 1.18  1.17 1.12, 1.23 
Log insulin resistance (mean (SD) = 0.86 (0.83))  1.34 1.23, 1.46  1.41 1.33, 1.49 
       
All mediators entered in one model       
Total Cholesterol (mean (SD) = 215 (42) mg/dL)  1.40 1.30, 1.52  1.31 1.24, 1.38 
HDL cholesterol (SD = 17 mg/dL))  0.67 0.61, 0.72    
Log triglycerides (mean (SD) = 4.7 (0.5))  1.00 0.90, 1.10  0.97 0.91, 1.04 
Systolic blood pressure (SD = 19 mmHg)  1.35 1.27, 1.45    
Diastolic blood pressure (mean (SD) = 74 (11) mmHg)  0.89 0.82, 0.96  0.94 0.88, 1.01 
Log insulin resistance (mean (SD) = 0.86 (0.83))  1.14 1.05, 1.24  1.26 1.18, 1.34 
HRs are shown for standard deviation contrasts.  For risk factors that had a quadratic relationship, two different contrasts are shown: 
from -1SD to the mean and from the mean to +1SD.   
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Table 4.5.  Predicted direct (unmediated) CHD hazard ratios (HRs) for 5-unit contrasts of BMI in mediation models, the 
Atherosclerosis Risk in Communities Study 
     BMI contrast   
  25 vs. 20 kg/m2  30 vs. 25 kg/m2  35 vs. 30 kg/m2 
  HR 95% CI  HR 95% CI  HR 95% CI 
No mediator  1.39 1.26, 1.54  1.29 1.22, 1.37  1.20 1.15, 1.26 
All mediators together  0.94 0.85, 1.06  0.96 0.89, 1.03  0.98 0.92, 1.03 
Mediators entered singly:         
Total cholesterol (mg/dL)  1.34 1.21, 1.48  1.27 1.20, 1.35  1.21 1.15, 1.26 
HDL cholesterol (mg/dL)  1.17 1.05, 1.29  1.14 1.07, 1.22  1.12 1.07, 1.17 
Log triglycerides  1.19 1.08, 1.32  1.16 1.09, 1.24  1.13 1.08, 1.19 
Systolic blood pressure (mmHg)  1.32 1.19, 1.46  1.23 1.16, 1.31  1.15 1.09, 1.20 
Diastolic blood pressure (mmHg)  1.37 1.23, 1.51  1.27 1.19, 1.35  1.18 1.12, 1.24 
Log insulin resistance   1.10 0.99, 1.23  1.07 0.99, 1.14  1.03 0.98, 1.09 
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Table 4.6.  Predicted indirect (mediated) CHD hazard ratios (HRs)* for 5-unit contrasts of BMI through established risk 
factors, the Atherosclerosis Risk in Communities Study 
     BMI contrast   
  25 vs. 20 kg/m2  30 vs. 25 kg/m2  35 vs. 30 kg/m2 
  HR 95% CI  HR 95% CI  HR 95% CI 
Mediators entered singly       
Total cholesterol (mg/dL)  1.05 1.03, 1.06  1.02 1.02, 1.03  1.00 1.00, 1.01 
HDL cholesterol (mg/dL)  1.24 1.19, 1.29  1.17 1.14, 1.20  1.10 1.08, 1.12 
Log triglycerides (log mg/dL)  1.18 1.14, 1.23  1.12 1.09, 1.14  1.06 1.05, 1.07 
Systolic blood pressure (mmHg)  1.06 1.04, 1.07  1.05 1.04, 1.06  1.05 1.04, 1.06 
Diastolic blood pressure (mmHg)  1.02 1.01, 1.03  1.02 1.01, 1.03  1.02 1.01, 1.03 
Log insulin resistance (log mU*mmol/L2)  1.22 1.14, 1.29  1.19 1.15, 1.24  1.16 1.13, 1.19 
All mediators entered in one model       
Total cholesterol (mg/dL)  1.05 1.04, 1.07  1.03 1.02, 1.03  1.00 1.00, 1.01 
HDL cholesterol (mg/dL)  1.24 1.18, 1.29  1.16 1.13, 1.20  1.10 1.07, 1.12 
Log triglycerides (log mg/dL)  1.00 0.95, 1.04  0.99 0.97, 1.02  0.99 0.98, 1.01 
Systolic blood pressure (mmHg)  1.06 1.05, 1.08  1.06 1.04, 1.07  1.05 1.04, 1.06 
Diastolic blood pressure (mmHg)  0.98 0.97, 0.99  0.99 0.98, 1.00  0.99 0.98, 1.00 
Log insulin resistance (log mU*mmol/L2)  1.09 1.03, 1.16  1.11 1.07, 1.15  1.11 1.08, 1.14 
*HRs are predicted at mean values of covariates 
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Figure 4.2.  Predicted indirect (mediated) CHD hazard ratios (HRs)* for 5-unit 
contrasts of BMI through established risk factors, the Atherosclerosis Risk in 
Communities Study
 
 
              *HRs are predicted at mean values of covariates 
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V. IMPACT OF ANTIHYPERTENSIVE MEDICATION USE ON ASSOCIATIONS OF BODY MASS 
INDEX WITH BLOOD PRESSURE AND CORONARY HEART DISEASE IN THE ATHEROSCLEROSIS 
RISK IN COMMUNITIES (ARIC) STUDY 
A. Abstract
Antihypertensive medication use is highly prevalent, so it is important to understand 
the impact of medication use on observed associations of body mass index (BMI) with blood 
pressure (BP) and coronary heart disease (CHD) in the population.  The objective of this 
study was to use of a variety of analytic strategies to aid in interpretation of observed 
associations.  Data were from the Atherosclerosis Risk in Communities Study, a cohort of 
15,792 White and African American adults aged 45-64 in 1987-89, followed through 2005.  
We used linear regression and Cox proportional hazards regression to compare untreated to 
treated participants.  Models were adjusted for age, age2, gender, race, field center, physical 
activity, insurance, education, smoking, alcohol and family history of hypertension and 
myocardial infarction.  In cross-sectional and mediation analyses, associations of BMI with 
BP and CHD were markedly attenuated in the treated compared to the untreated population.  
When the untreated population was limited to hypertensives, however, associations of BMI 
with BP were lower than in treated participants.  New users of medication had similar 
associations between BMI and both SBP and DBP before and after initiating medication use; 
these associations were similar in magnitude to those seen in the treated participants.  
Associations of BMI with BP and CHD at the population level may be markedly reduced in 
treated compared to untreated individuals, but this may not be driven by effects of 
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medication use.  Analysts should carefully consider the handling of medication status in 
analyses of observational data. 
B. Background 
Thirty percent of U.S. adults 20 years and over had high blood pressure (systolic 
blood pressure (SBP) ≥140mmHg, diastolic blood pressure (DBP) ≥90mmHg or on blood 
pressure medication) in 1999-2002; another 28% of U.S. adults were pre-hypertensive (SBP 
120-139 mmHg or DBP 80-89 mmHg) (Centers for Disease Control 2007).  High blood 
pressure is associated with excess body mass (Ledoux, Lambert et al. 1997; Mokdad, Ford et 
al. 2003; Zhu, Heshka et al. 2004) and predicts coronary heart disease (CHD) (Pi-Sunyer 
1993; Folsom, Stevens et al. 1998; Kim, Meade et al. 2006; Mann, Lee et al. 2006), the 
largest single cause of death in the United States (AHA 2007).  Analyses of predictors and 
effects of high blood pressure (BP) must account for use of antihypertensive medications.  
Hypertension medication use has risen markedly in the last decade, especially among 
overweight and obese individuals (Hajjar, Kotchen et al. 2006; Ong, Cheung et al. 2007).   
Associations among body mass index (BMI), blood pressure, CHD and 
antihypertensive medication use in the community are complex.  The Joint National 
Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure 
(JNC) recommends that physicians add and/or change medications as needed to achieve a 
goal blood pressure of <140/90 mmHg (Chobanian, Bakris et al. 2003).  Initial BP is likely to 
be higher in obese persons, but the goal is lower (<130/80 mmHg) for patients with diabetes 
or chronic kidney disease, both of which are associated with obesity (Chobanian, Bakris et al. 
2003), so goals for change in blood pressure may be substantially higher in obese persons.  
Further, some medications may be contraindicated and/or less effective in overweight or 
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obese persons (Pi-Sunyer 2007).  Given these complexities, it may be useful to examine and 
describe how medication use is associated with relationships among BMI, blood pressure and 
CHD at the community level.  
Ideally, we would like to know not only how medication use is associated with these 
relationships, but if the medication itself is the cause of those differences.  However, causal 
inferences about medication use from cohort data require caution because of confounding by 
indication.  Medication use may be associated with increased rather than reduced blood 
pressure in a community sample because antihypertensive medications are indicated for high 
blood pressure, and even with treatment the average blood pressure of treated persons may be 
higher than that of the rest of the population.  A medication use variable may then function as 
an indicator of hypertension rather than reflecting effects of medication on blood pressure.  
Observed associations of medication use with other variables in the community would 
therefore be at least partly confounded (Tobin, Sheehan et al. 2005).  For this reason, 
analyses of medication use in cohort data are few.  However, given the high prevalence of 
antihypertensive use (18% of all U.S. adults (Cutler, Sorlie et al. 2008) and 45% of those 
aged 60 and over (Ostchega, Dillon et al. 2007) (author’s calculations from tables in cited 
references)), it is important to understand the impact of medication use on observed 
associations in the community.  A careful examination of observed associations could have 
substantive and methodological value, and use of a variety of analytic strategies can aid in 
interpretation of observed associations.  We are not aware of any study that has published 
such data.  
The objective of this research was to investigate the impact of antihypertensive 
medication use in cohort data on the observed relationships among BMI, blood pressure and 
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coronary heart disease.  We used several methodologies to examine differences by 
antihypertensive medication status in associations between BMI and blood pressure.  We also 
examined differences by medication use status in mediation by blood pressure of the 
relationship between BMI and CHD events.   
C. Methods 
1. Study population 
The Atherosclerosis Risk in Communities (ARIC) Study is a prospective 
investigation of atherosclerosis and cardiovascular disease in a cohort of 15,792 African 
American and White adults aged 45-64 at baseline (1987-1989).  Participants were from four 
communities in the United States: Forsyth County, NC, Jackson, MS, Minneapolis, MN, and 
Washington County, MD.  Participants were examined at four study visits spaced 
approximately 3 years apart.  Details of the study design have been described previously 
(ARIC Investigators 1989).  Races other than African American or White (n=48) and African 
Americans in Minneapolis and Washington County (n=55) were excluded per standard ARIC 
protocol because their numbers are too small to allow ethnic and field-center specific 
analyses.  The study was approved by the Institutional Review Board (IRB) at each field 
center, and this analysis was approved by the University of North Carolina Public Health-
Nursing IRB on research involving human subjects.   
2. Measurements 
Body weight was measured at all clinic visits in a scrub suit to the nearest pound by 
use of a beam balance scale.  Height (without shoes) was measured to the nearest centimeter 
using a metal rule and a standard triangular headboard.  BMI was calculated as weight in 
kilograms divided by height at baseline in meters squared.  Systolic and diastolic blood 
 69 
pressures were measured three times after a 5-minute rest using a random zero 
sphygmomanometer on the right arm of the seated participant.  The last two measures were 
averaged and recorded.   
Coronary heart disease is defined as: cardiac death, non-fatal myocardial infarction 
(MI), silent MI detected by echocardiogram, or cardiovascular surgery or coronary 
angioplasty (White, Folsom et al. 1996).  Follow-up on CHD events was available through 
December 31st, 2005.  For hazard analyses, time to event is defined as time from the 
subject’s baseline visit to the event date or to the censored date.  Subjects were classified as 
taking antihypertensive medications if they self-reported taking antihypertensive medications 
in the last two weeks or if the medications they brought to their clinic visit included an 
appropriately classified medication (alpha blocker, beta blocker, calcium channel blocker, 
ace inhibitor, angiotensin II receptor blocker, centrally acting adrenolytic, vasodilator or 
diuretic).   
Age (date of birth), race/ethnicity, and gender were self-reported.  Additional 
covariates were assessed by interviewer-administered questionnaires.  We categorized 
education as less than a high school education, high school graduate, or at least some college.  
Physical activity was assessed with the Baecke leisure time physical activity questionnaire 
(Baecke, Burema et al. 1982) and categorized in tertiles.  A 66-item, semi-quantitative food 
frequency questionnaire was used to assess diet (Willett, Sampson et al. 1985).  We 
examined total energy and sodium, but these variables were dropped because they had no 
impact on any of the associations examined.  Self-reported cigarette smoking status and 
alcoholic beverage consumption were categorized as current, former, or never.  Participants 
were asked about a number of possible sources of health insurance, categorized for this 
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analysis as insured or uninsured.  Participants were also asked if either parent had a history of 
myocardial infarction and of hypertension, each of which was categorized as yes or no.  A 
race-field center variable was created because not all field centers had both race groups.   
3. Datasets and exclusions    
For the baseline data, we excluded participants missing BMI (n=40), SBP or DBP 
(n=9), antihypertensive medication status (n=8) or covariates (n=157).  The final baseline 
dataset contained 15,475 participants.   
For the analysis that included data from all study examinations, we created a 
“stacked” dataset such that each participant had between 1 and 4 repeated observations.  We 
excluded observations missing BMI (obs=172), SBP or DBP (obs=17), antihypertensive 
medication status (obs=8) or covariates (obs=963).  The final dataset contained 15,475 
participants with 53,180 observations.   
For the new user data, we constructed a dataset comprising individuals who reported 
taking antihypertensive medication at examination 2, 3 or 4 and were not taking medication 
at any of their prior visits (n=2,773).  We excluded individuals missing blood pressure (n=2), 
BMI (n=11) or covariates (n=41) at either visit, for a total sample of 2,719.   
4. Statistical analyses 
a. 
We examined differences by antihypertensive medication status in the association of 
BMI with systolic and diastolic blood pressure four different ways using baseline and stacked 
datasets.  We first compared the treated population to the entire untreated population, which 
included untreated hypertensives and normotensives, and then stratified on blood pressure 
level (stacked dataset only) in order to compare treated persons to untreated hypertensives.  
BMI - blood pressure analyses 
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We also examined the association between BMI and blood pressure in the new users pre- and 
post-treatment.   
Linear regression (PROC REG in SAS 9.1, SAS Institute, Cary, NC) was used with 
the baseline and new user data to evaluate the association of BMI with systolic and diastolic 
blood pressure in untreated compared to treated participants.  For the stacked data, we used 
linear regression in SAS PROC MIXED.  We used fixed effects with repeated measures and 
specified an unstructured correlation matrix, which provided the best model fit. We repeated 
these analyses dividing the untreated participants into untreated normotensives (SBP<140 
mmHg and DBP<90 mmHg) and untreated hypertensives (SBP≥140 mmHg or DBP≥90 
mmHg).  We divided the treated participants in the same way for comparison.   
For all cross-sectional analyses, BMI and BP variables were continuous.  Higher 
order terms were considered for BMI and for age, and a BMI-age interaction was also 
assessed.  Differences by medication status were assessed using the Wald test.  All cross-
sectional analyses were adjusted for age, age-squared, gender, race-field center, family 
history of hypertension, smoking, alcohol use, physical activity, education and insurance 
status.  The stacked and new user analyses were also adjusted for calendar year. 
b. 
We examined total, indirect (mediated by blood pressure) and direct (not mediated by 
blood pressure) effects of BMI on CHD by antihypertensive medication status.  Systolic and 
diastolic blood pressures were examined as mediators in separate and combined models.     
Mediation analyses 
For the mediation analysis, exclusions were the same as in the baseline data with the 
additional exclusion of persons with prevalent (n=756) or missing (n=310) CHD at baseline.  
Final sample sizes were 10,302 untreated and 4,107 treated participants.  There were 1,246 
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(12.1%) incident CHD cases among the untreated participants and 787 (19.2%) among the 
treated participants.   
We used structural equation models in Mplus 5.0 to assess effects of baseline BMI on 
time to CHD through baseline blood pressure variables.  Structural equation models 
incorporate several regression equations simultaneously to obtain path coefficients for each 
relationship.  The conceptual model for the mediation analysis is illustrated in Figure 5.1.  
Linear regression was used to examine the relationship between continuous BMI and blood 
pressure variables (path A), and Cox proportional hazards regression was used to examine 
the relationships between blood pressure and CHD (path B) and between BMI and CHD 
(path C’, the direct effect).  Path C (the total effect, not shown) is the path from BMI to CHD 
in a model with no mediator. 
The indirect (mediated) effect of BMI on CHD through a given blood pressure 
measure was calculated by multiplying the path coefficients from paths A and B, where A is 
the change in the blood pressure measure for a 5-unit increment of BMI, and B is the change 
in the log hazard ratio (HR) of CHD for a 1-unit increment of blood pressure.  The indirect 
effect is therefore the change in the log CHD hazard ratio for a 5-unit increment of BMI, 
acting through that blood pressure measure.  Exponentiation of this parameter yields an 
indirect hazard ratio for the effect of BMI on CHD through that measure.  The standard error 
for the indirect effect was calculated using the delta method.  All mediation models were 
stratified by baseline antihypertensive medication status and were adjusted for the same 
variables as the cross-sectional analysis plus family history of myocardial infarction in 
portions of the model with CHD as the outcome.  Differences by medication status were 
assessed using a Wald test.   
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D. Results 
1. BMI - blood pressure analysis 
Sample characteristics at baseline and for the new user analysis are shown in Table 
5.1 by antihypertensive medication treatment status.  The stacked data (not shown) were 
similar to the baseline data in patterns of demographic and behavioral characteristics by 
treatment group.  In the baseline data, treated participants had higher mean BMI than 
untreated participants.  They were also older and more likely to be African American, 
female, without health insurance and to report low levels of physical activity.  They were less 
likely to report being current smokers or drinkers.  The new users reported some changes in 
behaviors between visits, in particular reductions in the prevalences of current smoking and 
drinking.  There were small decreases in physical activity and in the percent uninsured.  
Table 5.2 shows the levels of SBP and DBP in the untreated compared to the treated 
observations for each of the three analysis datasets.  Systolic blood pressure was 10 mmHg 
higher in the treated than in the untreated observations for both the baseline and stacked data, 
and diastolic was 3-5 mmHg higher in the treated observations.  In contrast, there was a 6 
mmHg drop in blood pressure from the pre-treatment visit to the post-treatment visit in the 
new users.   
In the models not stratified by treatment status, the antihypertensive medication status 
- BMI interaction was highly significant (p<0.0001) for both blood pressure measures in the 
baseline and stacked data.  The cross-sectional associations between BMI and SBP and DBP 
(Table 5.3) were much stronger in untreated than in treated participants for the baseline and 
stacked data.  At baseline, for every 1-unit increment in BMI, SBP increased by 0.71 mmHg 
(95% CI: 0.65, 0.78) in the untreated compared to a substantially lower increase (0.31 mmHg 
 74 
(95% CI: 0.21, 0.41)) in subjects taking antihypertensive medication.  Similar patterns were 
observed for DBP (0.35 mmHg (95% CI: 0.31, 0.38) in the untreated vs. 0.09 mmHg (95% 
CI: 0.03, 0.14) in the treated).  Associations in the stacked data were somewhat stronger than 
in the baseline data, but differences by treatment status followed the same pattern in both 
datasets.  In contrast to the results from the baseline and stacked data, the associations 
between BMI and both SBP and DBP were not different in the new users at their post-
treatment visit compared to their pre-treatment visit (approximately three years earlier).  The 
magnitude of the BMI-BP associations observed in the new users at both visits was similar to 
what was seen in the treated participants in the other two analyses. 
Table 5.4 shows the results from the stacked analyses stratified by blood pressure 
levels.  There were many more normotensive than hypertensive observations.  In both high 
and low blood pressure observations, the association was reduced in the treated compared to 
the untreated.  The associations between BMI and both systolic and diastolic blood pressure 
among the observations with high blood pressure were markedly reduced compared to the 
associations seen in those with lower blood pressure.  However, we did not see a curved 
relationship when we assessed the quadratic association of BMI with BP in the unstratified 
models.     
2. Mediation analysis results 
All effects of BMI (total, indirect and direct, as well as A paths) were substantially 
stronger in untreated than in treated participants.  The adjusted HR for the effect of a 5-unit 
increment of BMI on CHD with no mediators in the model (the total effect) was 1.23 (95% 
CI: 1.16, 1.31) in untreated participants and a significantly lower 1.09 (95% CI: 1.03, 1.15) in 
treated participants (p=0.003, Figure 5.2a).   
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Figures 5.2b - 5.2d show beta coefficients for the effect of a 5-unit increment of BMI 
on SBP and DBP (the A paths) and HRs for the effects of 10-unit increments of SBP and 
DBP on CHD (B paths).  While the effects of BMI on systolic and diastolic blood pressure 
(A paths) were substantially larger in untreated than in treated participants, in contrast, the B 
path effects of blood pressure on CHD were almost identical in the treated and untreated 
participants.   
The direct effect of BMI on CHD was attenuated in mediation models (C’ paths, 
Figures 5.2b-5.2d) compared to the model without mediators (C path, Figure 5.2a), but BMI 
remained a significant direct predictor of CHD for both untreated and treated participants.  
The direct effect of BMI was not attenuated by addition of DBP to the model containing SBP 
(comparing Figure 5.2d to 5.2b) in either untreated or treated participants. 
Table 5.5 shows the indirect (A times B) effects of BMI on CHD through blood 
pressure.  All confidence intervals excluded the null except for the effect through treated 
DBP with SBP in the model.  Indirect effects were greater through systolic than through 
diastolic blood pressure and in untreated than in treated participants.  The smaller indirect 
effects in treated participants were almost entirely due to the much smaller A coefficients.  In 
the combined model, the indirect effect through SBP was increased when DBP was added to 
the model in the untreated participants, while the indirect effect through DBP became weakly 
protective.   
E. Discussion 
Physicians are advised to adjust patient medications until goal levels of blood 
pressure are reached (Chobanian, Bakris et al. 2003).  Therefore, in a community sample, we 
expected to see reduced associations of BMI with blood pressure and with CHD mediated by 
 76 
blood pressure in treated individuals compared to untreated individuals, which is indeed what 
was observed.  In the baseline and stacked data analyses, associations between BMI and 
blood pressure were substantially smaller in participants using antihypertensive medication 
compared to participants not taking such medication.  We expected that the new user analysis 
we conducted would confirm these findings, but we observed no difference in the 
associations of BMI with systolic or diastolic blood pressure between the participants pre- 
and post-treatment.   
The associations observed in the new user data were comparable in magnitude to 
those observed in the treated individuals in the other two analyses and greater than those 
observed in the untreated hypertensives.  These observations suggested that the differences 
we observed in the baseline and stacked data might have been due to factors other than 
effects of medication use on blood pressure.  Differences between the populations, rather 
than effects of treatment, might have lead to the observed differences.  The two populations 
were different on many baseline characteristics (Table 5.1), including blood pressure.  We 
adjusted for these characteristics in the pooled analyses, but there were undoubtedly some 
unmeasured differences.   
Observed differences could also have been the result of truncation of the data 
associated with subdividing the populations.  A plot of SBP on BMI at baseline illustrates 
this problem (Figure 5.3).  The lowest blood pressures occur only in individuals with low 
BMI, whereas high blood pressure occurs across the range of BMI.  It is readily apparent 
from the figure that subdividing these individuals into high and low blood pressure will result 
in very different observed effects of BMI on SBP in the two groups, as we have indeed seen 
(Table 5.4).  However, this apparent interaction is not indicative of a curved relationship 
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between BMI and blood pressure in either treated or untreated participants.  Lower observed 
associations of blood pressure with BMI in the treated and new user groups may be driven by 
the elimination of some individuals with very low blood pressure from the dataset rather than 
by reductions in blood pressure caused by use of medication.   
We conducted an additional analysis of the association of BMI with change in BP in 
new users compared to individuals who never reported treatment and to those who remained 
on antihypertensive medication across consecutive study examinations.  Both SBP and DBP 
decreased in the new users (-5.1 mmHg and -4.7 mmHg, respectively).  SBP increased 
slightly among participants whose medication status did not change (3.7 mmHg for those 
who were taking antihypertensive medication at both visits and 2.4 mmHg for those who 
were not), but DBP did not change or decreased (0.08 mmHg and -1.3 mmHg, 
respectively).   Associations of mean BMI with change in blood pressure across consecutive 
visits were very small (less than 0.5 mmHg for a 5-unit increment of BMI) regardless of 
continuity or change in antihypertensive medication status.  Obesity can diminish physiologic 
response to medication but may also affect choice of medication and dosage (Pi-Sunyer 
2007).  These effects might cancel each other out, or might be too weak to cause any 
association of change in blood pressure with BMI.   
We are not aware of any other studies examining effects of BMI on blood pressure by 
medication status.  Randomized trials of antihypertensive medication do not often examine 
how treatment affects associations of blood pressure with other risk factors such as BMI.  
Other studies with blood pressure outcomes typically dichotomize blood pressure into 
hypertensive (which includes people on medication) and not hypertensive, by-passing the 
need to address how medication use affects blood pressure.  Previous work in the ARIC 
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cohort examined effects of weight loss on blood pressure in treated participants compared to 
untreated.  Weight loss in treated participants was associated with slightly smaller decreases 
in blood pressure and less remission of hypertension than in untreated participants, but, as in 
this analysis, the authors could not account for reductions in medication number or dosage 
which may have occurred (Juhaeri, Stevens et al. 2003).   
Consistent with other longitudinal studies (Jousilahti, Tuomilehto et al. 1996; Bogers, 
Bemelmans et al. 2007), BMI predicted CHD in the ARIC study.  The association was 
mediated, in part, by blood pressure, particularly systolic pressure.  Overall, the association 
between BMI and CHD was attenuated in treated individuals.  This was true for the direct 
path (not through BP), as well as for the indirect (BP mediated) path.  Other papers 
addressing mediation of the effect of BMI on CHD by blood pressure have found similar 
mediation effects, but have not addressed the possible impact of medication use on their 
analyses (Jousilahti, Tuomilehto et al. 1996; Tanne, Medalie et al. 2005; Kim, Meade et al. 
2006).  A meta-analysis of 21 cohort studies (Bogers, Bemelmans et al. 2007) found a 
relative risk of CHD for a 5-unit change in BMI of 1.29 (95% CI: 1.22, 1.35).  Comparable 
HRs from the present analysis tended to be slightly smaller.  In the meta-analysis the HR for 
BMI was attenuated to 1.16 (95% CI: 1.11, 1.21) with both blood pressure and cholesterol in 
the model.  We conducted a supplementary analysis (not shown) in which the addition of 
total cholesterol, high-density lipoprotein cholesterol and insulin resistance (from the 
Homeostasis Model Assessment equation) to the model eliminated the direct effect of BMI, 
but SBP and DBP paths changed very little.   
Associations between blood pressure and CHD in this study were not different in the 
treated and untreated groups.  A few studies have examined differences by treatment status in 
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the effects of blood pressure on CHD (the “B” paths in this analysis).  In the Copenhagen II 
cohort, HRs increased with increasing blood pressure categories in untreated subjects, but 
were null in treated subjects (Jensen, Nyboe et al. 1991).  These results differed from the 
present study, which found no difference.  An analysis of the NHANES I Follow Up Study 
data (baseline age 33-87) found HRs for the effects of SBP and DBP on CHD in treated 
participants very similar in magnitude to those presented here (Greenberg 2005).  The HRs in 
untreated hypertensives (they excluded normotensives) were greater than what we found, but 
did not appear to be statistically different from their treated participants (they did not test this 
hypothesis formally, but confidence intervals were shown).  In addition, a secondary analysis 
of randomized medication trial data in 4,632 adults ≥60 years with isolated systolic 
hypertension attempted to address differences in effects of BP on CHD by treatment status, 
but after 5 years there were no significant effects of blood pressure on CHD in the treatment 
or placebo groups (Vaccarino, Berger et al. 2001). 
The direct effect of BMI on CHD (i.e., the effect not mediated by either SBP or DBP) 
was lower in treated participants.  This implies that antihypertensive medication was 
associated with both BMI and CHD independently of blood pressure and other variables for 
which we adjusted, and may therefore be confounded.  This agrees with our conclusion from 
the cross-sectional analyses that differences in treatment groups may be due to factors other 
than effects of medication use.  In addition to differences in covariate values, there were also 
differences in overall CHD risk between treated and untreated participants, and there are 
likely to be differences in other metabolic CHD risk factors that could mediate the BMI-CHD 
relationship.  Another possible complication is that some blood pressure medications also 
have effects on weight, lipids and glucose (Pi-Sunyer 2007).  Diuretics can reduce (water) 
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weight, increase insulin resistance and, in high doses, contribute to dyslipidemia.  Beta-
blockers can cause weight gain, contribute to impaired glucose metabolism and can raise 
triglycerides and lower HDL-cholesterol.  Alpha-blockers, on the other hand, can increase 
insulin sensitivity and lower triglycerides and LDL-cholesterol (Pi-Sunyer 2007).  Further, 
participants treated with antihypertensive medications were more likely to be taking glucose 
and lipid-lowering medications in our data.  Effects of all of these medications on risk factors 
for CHD may serve to dilute the association between obesity and CHD in treated individuals.  
Future work in this area should carefully consider the types of antihypertensive medications 
used. 
There has been much discussion in the literature concerning the correct way to 
measure the effect of obesity on overall mortality and to estimate the number of lives lost due 
to obesity (Durazo-Arvizu, McGee et al. 1998; Allison, Fontaine et al. 1999; Flegal, 
Graubard et al. 2005).  It is generally agreed that mediators (e.g. blood pressure) should not 
be included in models as covariates when estimating the risk associated with elevated BMI 
on an outcome such as CHD or mortality.  There is less agreement concerning the possibility 
that pharmaceutical treatments for hypertension and cholesterol may impact results (Mark 
2005; Flegal, Graubard et al. 2007; McTigue and Kuller 2008; Whitlock, Lewington et al. 
2009) or help to explain the decrease in the association of obesity with mortality over time 
observed in some analyses (Ding 2005).  This raises the question of whether the intent of the 
study is to estimate the risk of BMI in the population as it currently exists (with about 1/5 of 
US adults taking antihypertensive medications) or to estimate the theoretical, potential effect 
of elevated BMI were medications not used.  The former estimate can be obtained given 
population-based data, whereas the latter effect is more difficult to estimate in a population 
 81 
like that of the United States.  If the association of BMI with blood pressure is markedly 
lower in those who use antihypertensive medications, statistical adjustment for medication 
use would likely yield an observed effect of BMI on outcomes associated with blood pressure 
(such as CHD and mortality) that is intermediate between the effect expected in the non-
medicated and the attenuated effect seen among the medicated.  Analyses of only non-
medicated individuals could result in an underestimate of the effect that would be found were 
the entire sample not on medication, since a large portion of individuals prone to 
hypertension will have been removed from the sample.  The proper handling of medication in 
these situations depends on whether observations of differences across medication status 
reflect effects of medication or are confounded by indication.  Our results suggest that at least 
partial confounding is likely.  Examination of young adults in whom medication use is rare 
could be helpful in sorting out these effects, but long follow-up periods would be needed to 
collect CHD or mortality events, and information on the initiation of medications over time 
collected.   
This analysis had several limitations.  The untreated participants in this analysis 
include both normotensive and hypertensive individuals.  We examined associations in these 
subgroups separately, but untreated hypertensives are not directly comparable to treated 
participants.  The former may be untreated for a variety of reasons and may have previously 
been treated.  In short, this population is representative of the community, but is not properly 
controlled to assess causal effects of medication use.  We had no information on medication 
dosage per se, and incomplete data on types of antihypertensive medications did not allow us 
to examine this variable.  The age range of the cohort studied here allowed the observation of 
CHD events, but meant that obesity, blood pressure and medication status earlier in life were 
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not measured.  The simultaneous inclusion of SBP and DBP in the combined model could 
have lead to bias in one or both of the estimates of BP effects on CHD (B paths) due to 
correlated errors.  Though we cannot rule out such bias, the combined model estimates are 
consistent with known effects of pulse pressure (Vaccarino, Holford et al. 2000; Miura, Dyer 
et al. 2001; Lewington, Clarke et al. 2002).     
Medication use was assessed as usage in the past two weeks, and while we excluded 
persons who were taking medication at prior visits, we cannot be sure that our “new” users 
have not taken medication at any point in the past.  Also, the new users may have been on 
medication for only a few weeks or for 3 or more years.  Medication doses may have been 
adjusted over time and such adjustments may have differed by weight status.  Further, blood 
pressure values in our new user analysis may be particularly subject to regression to the mean 
from the first visit to the second because letters were sent to the physicians of participants 
with high observed blood pressure at each visit; individuals whose measured blood pressure 
was at the high end of their usual range at a particular visit may have been more likely to be 
on medication at the next visit than individuals with the same usual blood pressure but no 
spuriously high measurement at their prior ARIC visit.  In sum, while the new user analysis 
adds to our understanding of the impact of medication use in this cohort, our finding that 
medication use does not change the association between BMI and blood pressure in this 
group is not strong evidence of a null effect. 
Strengths of this study include the excellent data quality and multiple examinations in 
the ARIC cohort.  The use of several different analytic methods to examine how medication 
use modified associations of BMI with blood pressure and CHD provided a broad picture of 
its potential impact on analyses of cohort data.  We caution against interpretations of our 
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results as addressing causal effects of medication use.  Antihypertensive medication use in 
the community is profoundly confounded by indication – i.e., only persons with high blood 
pressure are given antihypertensive medication, and thus medication use is highly associated 
with disease at the community level.  This contrasts sharply with actual effects of medication 
use, which reduce disease in randomized controlled trials (Neaton, Grimm et al. 1993).  We 
reported the associations of BMI with blood pressure and CHD by antihypertensive 
medication use status and used various strategies to try to understand how medication use 
might be affecting the associations in this cohort.   
This study illustrates the impact of antihypertensive medication use on observed 
associations among BMI, BP and CHD in population-level data and does not necessarily 
imply that body mass is less important as a risk factor for disease in treated individuals.  
Indeed, excess body weight may have been an important factor in the manifestation of 
hypertension and the need for antihypertensive medication in many of our participants.  
Further, given that high blood pressure is more resistant to effects of treatment in obese 
individuals (Cushman, Ford et al. 2002; Pi-Sunyer 2007), an analysis of subjects randomized 
to treatment might expect to find a stronger association of body mass with BP in treated 
individuals rather than the weaker association seen here.  An analysis of randomized trial 
data could address causality but may suffer from different limitations due to a narrower range 
of starting BP levels and potential lack of generalizability.  We are not aware of any such 
analyses to date.   
Future analyses in cohort data might also prove illuminating.  When we compared the 
associations seen in the treated population and new users to the subset of the untreated 
population that had high blood pressures levels (those more likely to become new users), we 
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observed that the associations between BMI and BP in the untreated hypertensive individuals 
were even lower than the associations in the treated and new user populations.  This analysis 
could be further refined with the use of propensity scores (predicting likelihood of treatment 
using a vector of covariates) to provide a better matched untreated group for comparison to 
the treated population.    
Associations of BMI with blood pressure and CHD were attenuated in individuals 
treated with antihypertensive medications compared to individuals not taking such 
medications in this cohort, even for the effect on CHD independent of blood pressure.  In 
contrast, analyses of the association between BMI and BP limited to the same individuals 
before and after beginning treatment showed no differences by treatment status, providing 
evidence that the attenuation observed in the overall cohort may have been attributable to 
factors other than causal effects of medication use.  However, the intra-individual analysis 
also suffered from limitations.  More research, possibly including secondary analyses of 
clinical trial data, could help to clarify the causal relationships.  Meanwhile, analysts of 
observational data should consider the potential impact of the handling of antihypertensive 
medication treatment on analyses of body mass index and cardiovascular outcomes 
regardless of whether blood pressure is explicitly included in the analysis.   
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Figure 5.1 legend: Conceptual model for the mediation analysis.  BMI, BP and covariates 
were measured at baseline.  Linear regression was used to examine the relationship between 
BMI and blood pressure variables (path A), and Cox proportional hazards regression was 
used to examine the relationships between blood pressure and CHD (path B) and between 
BMI and CHD (path C’).  Path C (not shown) is the path from BMI to CHD in a model with 
no mediator.   
 
 
 
 
Figure 5.1: Mediation analysis paths 
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Table 5.1.  Means (SD) and frequency distributions of selected sample characteristics by antihypertensive treatment status in 
the Atherosclerosis Risk in Communities Study 
 Baseline data New user data 
  
Variable 
Untreated  
(N=10,733) 
Treated 
(N=4,742) 
Time 1 (pre-
treatment) 
Time 2 (post-
treatment) 
Body mass index (kg/m2, mean (SD)) 27 (5) 30 (6) 29 (5) 29 (5) 
Age (years, mean (SD)) 54 (6) 55 (6) 57 (6) 60 (6) 
Race (% African American) 22 38 26 26 
Gender (% female) 53 60 50 50 
Education (% < high school) 20 32 22 22 
Health insurance (% without)    9 12 8 7 
Alcohol use (% current drinkers) 60 47 55 50 
Cigarette smoking (% current smokers) 27 24 22 17 
Physical activity (% lowest tertile) 26 33 27 26 
Family history of hypertension (% with) 49 63 54 54 
Family history of myocardial infarction (% with) 38 42 – – 
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Table 5.2.  Mean (SD) systolic and diastolic blood pressure by antihypertensive treatment status for three analytic datasets in 
the Atherosclerosis Risk in Communities Study 
 Baseline data  Stacked data  New user data 
 Untreated Treated  Untreated Treated  Pre-treatment Post-treatment 
 (N=10,733) (N=4,742)  (obs=34,260) (obs=18,920)  (obs=2,719) (obs=2,719) 
Systolic blood 
pressure (mmHg) 
118 (17) 128 (20)  120 (17) 130 (20)  133 (20) 127 (18) 
Diastolic blood 
pressure (mmHg) 
72 (11) 77 (12)  71 (10) 74 (11)  78 (12) 72 (11) 
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Table 5.3.  Increase in systolic and diastolic blood pressure for a 1-unit increment of body mass index in the Atherosclerosis 
Risk in Communities Study 
 Baseline data  Stacked data  New user data 
 Untreated* Treated*  Untreated* Treated*  Pre-treatment Post-treatment 
 (N=10,733) (N=4,742)  (obs=34,260) (obs=18,920)  (obs=2,719) (obs=2,719) 
 β
BMI
 95% CI βBMI 95% CI 
 β
BMI
 95% CI βBMI 95% CI 
 β
BMI
 95% CI βBMI 95% CI 
Systolic 
blood 
pressure 
(mmHg) 
0.71 0.65, 0.78 0.31 0.21, 0.41  0.91 0.86, 0.96 0.38 0.32, 0.45  0.37 0.22, 0.51 0.34 0.21, 0.47 
Diastolic 
blood 
pressure 
(mmHg) 
0.35 0.31, 0.38 0.09 0.03, 0.14  0.43 0.40, 0.46 0.14 0.10, 0.17  0.12 0.04, 0.21 0.11 0.04, 0.18 
Adjusted for age, age-squared, gender, race-field center, family history of hypertension, smoking, alcohol use, physical activity, 
education and insurance status, as well as calendar year for the stacked and new user analyses. 
*P<0.001 for differences by antihypertension medication status (untreated vs.  treated), assessed using the Wald test. 
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Table 5.4.  Increase in systolic and diastolic blood pressure for a 1-unit increment of body mass index in the Atherosclerosis 
Risk in Communities Study 
 Antihypertensive medication status 
 Normotensive (SBP<140 and DBP<90) Hypertensive (SBP≥140 or DBP≥90) 
 Untreated  
(obs = 29,525) 
Treated 
(obs = 13,352) 
Untreated 
(obs = 4,735) 
Treated 
(obs = 5,568) 
 β
BMI
 95% CI βBMI 95% CI βBMI 95% CI βBMI 95% CI 
Systolic Blood Pressure (mmHg) 0.67 0.63, 0.71 0.31 0.27, 0.35 0.11 0.04, 0.19 -0.03 -0.10, 0.05 
Diastolic Blood Pressure (mmHg) 0.34 0.31, 0.37 0.11 0.08, 0.14 0.02 -0.04, 0.07 -0.07 -0.12, -0.01 
*Adjusted for age, age-squared, gender, race-field center, family history of hypertension, smoking, alcohol use, physical 
activity, education and insurance status. 
**Differences by antihypertension medication status (untreated vs.  treated) were assessed using the Wald test. 
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Figure 5.2:  Mediation paths by antihypertensive treatment status 
Figure 5.2a.  No mediation 
 
 
 
 
 
Figure 5.2b.  Mediation by systolic blood pressure 
 
 
 
 
 
 
 
 
Figure 5.2c.  Mediation by diastolic blood pressure 
 
 
 
 
 
 
 
 
 
Figure 5.2d.  Mediation by systolic and diastolic blood pressure 
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Figure 5.2a-d legend:  
Beta coefficients (A paths) and hazard ratios (HRs) (exponentiated B and C’ path 
coefficients) for structural equation models of the relationships among body mass index 
(BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP) and coronary heart 
disease (CHD).  BMI effects are for a 5-unit increment of BMI.  BP effects are shown for a 
10-unit increment of the BP measure.  All models were adjusted for age, age-squared, 
gender, race-field center, family history of hypertension and myocardial infarction, smoking, 
alcohol use, physical activity, education and insurance status.  Estimates in bold type are 
significantly different from zero. 
* Estimates are different between treatment groups (Wald test, α=0.05).   
  
 92 
Table 5.5.  Indirect effects* of body mass index on coronary heart disease through 
blood pressure, by antihypertensive treatment status in the Atherosclerosis Risk in 
Communities Study 
 Antihypertensive medication status  
 Untreated 
(N=10,302) 
Treated 
(N=4,107) 
P-value** 
 Indirect 
effect 
95% CI Indirect 
effect 
95% CI 
Single-mediator models:      
SBP alone (Fig.  2b) 1.05 1.04, 1.06 1.02 1.01, 1.03 <0.001 
DBP alone (Fig.  2c) 1.02 1.01, 1.03 1.01 1.00, 1.01 0.022 
Combined model:      
SBP (with DBP, Fig.  2d) 1.07 1.05, 1.09 1.02 1.01, 1.03 <0.001 
DBP (with SBP, Fig.  2d) 0.98 0.97, 1.00 1.00 1.00, 1.00 0.017 
Indirect effects are calculated as the A path times the unexponentiated B path (log of 
the B paths shown in Figure 2).  95% CIs were calculated using the delta method.   
* All models adjusted for age, age-squared, gender, race-field center, family history 
of hypertension and myocardial infarction, smoking, alcohol use, physical activity, 
education and insurance status. 
**Differences by antihypertension medication status (untreated vs.  treated) were 
assessed using the Wald test. 
SBP=systolic blood pressure.  DBP=diastolic blood pressure.  
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Figure 5.3.  Plot of systolic blood pressure on body mass index at baseline 
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VI. SYNTHESIS 
A. Overview 
The primary aim of this dissertation was to examine mediation of the effects of 
obesity on CHD through traditional physiologic mediators in a bi-racial cohort of older 
adults.  We observed complete mediation of BMI’s effects on CHD through the mediators 
examined.  I.e., there was no longer a direct effect of BMI on CHD when its indirect effects 
through the hypothesized mediators were all accounted for.  This is consistent with much of 
the existing literature on mediation of the BMI-CHD relationship.    
The most novel aspect of our primary aim lies in the comparison of individual 
mediation paths with all mediators examined together.  These results were particularly 
interesting because of the curved nature of the relationships we found among BMI, the 
mediators and CHD.  The total effect of BMI on CHD declined with increasing BMI, as did 
BMI’s associations with all of the mediators, particularly the lipids.  Effects of most 
mediators on CHD were also curved, but the direction of the curve varied.  Effects of total 
cholesterol and triglycerides on CHD declined at higher levels, but effects of diastolic blood 
pressure and insulin resistance increased.  Effects of HDL and systolic blood pressure were 
not curved at all.  
As a result of the curves in the individual paths, most of the mediation effects were 
also curved, but to different degrees, which led to the interesting finding that the indirect 
(mediated) effect of BMI observed at lower BMIs was predominantly through HDL 
cholesterol, whereas at higher BMIs, indirect effects through HDL and insulin resistance 
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were of similar magnitude.  Mediation by systolic blood pressure was moderate, but constant 
across levels of BMI.  Total cholesterol was also a moderate mediator at lower BMIs and was 
not a mediator at all above a BMI of 30 kg/m2.  Diastolic blood pressure and triglycerides 
were not mediators at any BMI after accounting for the other mediators. 
We expected to find race and/or gender differences in the indirect effects because of 
the race and gender differences that have been found in the prevalences of many of these 
variables and in some of the associations among them.  And indeed, when we did not model 
the curvature of the associations we examined, we did see differences, especially in effects of 
BMI on mediators, which tended to be lower in African American women than in the other 
race-sex groups.  The differences disappeared when effects of BMI were allowed to vary 
with levels of BMI (by means of addition of a quadratic BMI term to the model), revealing 
that the differences initially observed were likely at least partially an artifact of the different 
distribution of BMI in African American women.   
Our secondary aim was to determine how antihypertensive treatment might affect the 
various paths in our mediation analyses involving blood pressure.  We were particularly 
concerned about effects of BMI on blood pressure because treatment has been shown to 
attenuate observed effects of predictor variables on continuous blood pressure (Tobin, 
Sheehan et al. 2005).  Given the high prevalence of antihypertensive medication use in the 
ARIC cohort, the potential for bias was high.   
We found that associations of BMI with blood pressure were attenuated in 
participants taking antihypertensive medication compared to participants who were not 
taking such medication.  However, when the same comparison was made within individuals 
who transitioned from not taking antihypertensive medication to taking such medication, the 
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association of BMI with blood pressure in the treated observations was the same as when 
those individuals were not treated.  While this “new user” analysis does not establish 
causality, it indicated that the differences observed between untreated and treated cohort 
participants may not have been due to effects of treatment.   
B. Strengths 
The strengths of this dissertation include the large bi-ethnic cohort and the high 
quality of the ARIC data, the novel use of SEM with Cox proportional hazards analysis and 
the attention given to the proper handling of medication use in the analyses.  The use of path 
analysis in a structural equation model allowed us to examine and compare mediation 
through individual risk factors, which adds substantially to the literature on effects of obesity 
on CHD. 
C. Limitations 
Limitations of the study include the inability to completely account for medication 
use despite the attention devoted to understanding its impact; our analyses were limited to a 
description of how medication use influences associations of interest in cohort data and how 
those influences might be interpreted and addressed.  Limitations of the primary aim include 
the inherent limitations in drawing causal inferences from observational data, which may be 
exacerbated in an analysis in which multiple estimated parameters are used to calculate an 
additional parameter, as we have done for the indirect effects.   
D. Conclusion 
Overall, these results highlight the complexity of analyses of blood pressure in 
persons being treated with antihypertensive medication and underscore the importance of 
traditional physiologic risk factors, particularly HDL cholesterol and insulin resistance, as 
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mediators of the effect of obesity on CHD.  The variation we observed in mediation across 
levels of BMI has not been previously shown.  Our work adds significantly to the literature 
on mediation through use of an improved methodological approach.  Repetition of this 
approach in other large datasets with hard endpoints would add further to our understanding 
of how obesity affects morbidity and mortality. 
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APPENDICES  
Appendix A: Race and gender results for Chapter 4 mediation analyses 
We did not observe race or gender differences in mediation of the BMI-CHD 
relationship (Chapter 4) or in any of the paths assessed except for the effect of BMI on 
insulin resistance, which varied by gender (A path, Figure A.1.).  The effects of mediators on 
CHD (B paths, Figures A.2.a-d) and indirect effects of BMI on CHD through the indicated 
mediators (Figures A.3.a-d) are shown by race and gender below. 
 
Figure A.1.  Increment in log insulin resistance associated with 5-unit contrasts of body 
mass index (kg/m2) by race and gender, the Atherosclerosis Risk in Communities Study 
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Figure A.2.  Predicted CHD hazard ratios (HRs) for standard deviation increments of 
risk factors by race and sex in the Atherosclerosis Risk in Communities Study 
 
Figure A.2.a. 
 
 
 
Figure A.2.b. 
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Figure A.2.c. 
 
 
 
Figure A.2.d. 
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Figure A.3.  Predicted indirect (mediated) CHD hazard ratios (HRs) for 5-unit 
contrasts of body mass index (kg/m2) through established physiologic risk factors by 
race and sex in the Atherosclerosis Risk in Communities Study 
 
Figure A.3.a. 
 
 
 
Figure A.3.b. 
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Figure A.3.c. 
 
 
 
Figure A.3.d. 
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Appendix B: Alternative methods for handling antihypertensive medications in 
analyses of BMI, blood pressure and CHD 
The following tables include additional information on medication use in the ARIC 
cohort (Table B.1.) and the results of additional analyses of mediation under various 
scenarios for handling antihypertensive medication (Table B.2.).  We conducted the main 
mediation analysis presented in Chapter 5 in untreated and treated participants separately (as 
in Chapter 5) and in the entire population with and without statistical adjustment for 
treatment and using imputed values of the risk factors for the treated participants.  We used a 
simple imputation method, as our purpose was not to accurately estimate effects but to 
explore the impact of treatment methods.  Participants being treated with antihypertensive 
medication were assigned a value for SBP or DBP 10mmHg higher than their observed 
value.  Untreated persons retained their observed value. The sample sizes are slightly smaller 
than in Chapter 5 because participants taking lipid-lowering and diabetes medications were 
also excluded from the data presented here.   
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Table B.1.  Means (SD) and prevalences of selected baseline sample characteristics 
among participant taking and not taking medications to treat hypertension, 
dyslipidemia and/or diabetes, the Atherosclerosis Risk in Communities Study 
  
Variable Whole 
population 
(N=13,569) 
Taking 
no meds 
(N=9,399) 
Taking 
HT meds 
(N=3,796) 
Taking 
lipid 
meds 
(N=356) 
Taking 
DM 
meds 
(N=490) 
Body Mass Index (kg/m2) 28 (5) 27 (5) 29 (6) 28 (4) 31 (6) 
Age (years) 54 (6) 53 (6) 55 (6) 56 (5) 56 (5) 
SBP (mmHg) 121 (18) 118 (17) 128 (20) 122 (17) 130 (21) 
DBP (mmHg) 74 (11) 72 (11) 77 (11) 72 (9) 74 (11) 
Total cholesterol 215 (42) 212 (40) 219 (44) 235 (46) 220 (49) 
HDL cholesterol 52 (17) 53 (17) 50 (16) 47 (17) 45 (15) 
Triglycerides 129 (86) 120 (77) 148 (100) 185 (150) 184 (134) 
Homa-IR 3.6 (8.8) 2.6 (2.6) 5.3 (12) 5.6 (19) 20 (40) 
Education (% < HS) 22 19 30 22 41 
Education (% HS) 42 42 40 44 38 
Health insurance (% with) 91 92 88 95 83 
Drinkers (% current) 57 61 48 53 29 
Drinkers (% former) 18 16 21 23 32 
Smokers (% current) 25 26 24 20 20 
Smokers (% former) 32 32 31 38 30 
Leisure activity (% 
highest tertile) 28 31 22 31 16 
Leisure activity (% 2nd 
tertile) 44 43 45 45 46 
Family history of diabetes 
(%) 24 23 25 29 48 
Family history of 
hypertension (%) 54 49 64 58 56 
Family history of MI (%) 39 38 41 44 37 
CHD events (N(%)) 1,886 (14) 1,072 (11) 714 (19) 77 (22) 179 (37) 
TC = Total Cholesterol   HDL = HDL cholesterol   lnTG = Log triglycerides   SBP = Systolic 
blood pressure   DBP = diastolic blood pressure   lnIR = Log insulin resistance (HOMA-IR) 
 
  
105 
Table B.2.  Beta coefficients and HRs for mediation paths in a model of effects of BMI on CHD through blood pressure, under 
various scenarios for handling antihypertensive medication, the Atherosclerosis Risk in Communities Study 
Mediation 
Path (estimate) 
Endogenous 
Variable 
Exogenous 
Variable (∆) 
Unadjusted 
for HTmeds 
(n=13,569) 
Untreated 
participants 
only 
(n=9,773) 
Treated 
participants 
only (n=3,796) 
Adjusted for 
HTmeds 
variable 
(n=13,569) 
Imputation of 
treated BP* 
(n=13,569)  
A (β) SBP BMI  (5 kg/m2) 
3.31  
(3.02, 3.60) 
3.59  
(3.24, 3.94) 
1.66  
(1.13, 2.20) 
2.89  
(2.60, 3.19) 
4.08  
(3.77, 4.39) 
A (β) DBP BMI  (5 kg/m2) 
1.57  
(1.40, 1.74) 
1.80  
(1.58, 2.01) 
0.49  
(0.20, 0.78) 
1.32  
(1.14, 1.49) 
2.34  
(2.15, 2.54) 
B (HR) CHD SBP  (10 mmHg) 
1.18  
(1.14, 1.22) 
1.20  
(1.14, 1.25) 
1.13  
(1.08, 1.19) 
1.17  
(1.13, 1.21) 
1.17  
(1.13, 1.21) 
B (HR) CHD DBP  (10 mmHg) 
0.95  
(0.89, 1.01) 
0.91  
(0.83, 0.99) 
0.97  
(0.88, 1.07) 
0.94  
(0.88, 1.00) 
1.00  
(0.94, 1.06) 
Total effect (C 
path, HR) CHD 
BMI  
(5 kg/m2) 
1.22  
(1.17, 1.27) 
1.22  
(1.15, 1.29) 
1.10  
(1.04, 1.17) 
1.17  
(1.12, 1.22) 
1.22  
(1.17, 1.27) 
Direct effect 
(C’ path, HR) CHD 
BMI  
(5 kg/m2) 
1.16  
(1.11, 1.21) 
1.16  
(1.09, 1.23) 
1.08  
(1.02, 1.15) 
1.13  
(1.08, 1.18) 
1.14  
(1.09, 1.19) 
Indirect effect 
through SBP 
(AxB, HR) 
CHD BMI  (5 kg/m2) 
1.06  
(1.04, 1.07) 
1.07  
(1.06, 1.09) 
1.02  
(1.01, 1.03) 
1.05  
(1.03, 1.06) 
1.07  
(1.05, 1.08) 
Indirect effect 
through DBP 
(AxB, HR) 
CHD BMI  (5 kg/m2) 
0.99  
(0.98, 1.00) 
0.98  
(0.97, 1.00) 
1.00  
(0.99, 1.00) 
0.99  
(0.98,1.00) 
1.00  
(0.99, 1.01) 
* 10mmHg was added to SBP and to DBP if the individual was taking antihypertensive medication. 
SBP = systolic blood pressure; DBP = diastolic blood pressure; CHD = coronary heart disease; HR = hazard ratio; BMI = body mass 
index; HTmeds = antihypertensive medication. 
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Appendix C.  Change in blood pressure associated with BMI 
 
Table C.1 below presents the change analyses mentioned in the discussion of Chapter 
5.  We used stacked data to examine associations of mean BMI with change in BP across 
consecutive study examinations at which a participant either 1) remained off antihypertensive 
medication, 2) remained on antihypertensive medication or 3) transitioned from not taking to 
taking antihypertensive medication.   
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Table C.1..  Change in systolic and diastolic blood pressure between consecutive visits predicted by mean BMI for 
participants according to change in antihypertensive medication status in the Atherosclerosis Risk in Communities Study 
Medication 
transition from 
time 1 to time 2 
Adjusted mean 
change in SBP 
(mmHg) 
Change in Systolic Blood Pressure Adjusted mean 
change in DBP 
(mmHg) 
Change in Diastolic Blood Pressure 
β
BMI
 95% CI βBMI 95% CI 
No, No 3.7 0.05 0.03, 0.08 0.08 -0.01 -0.03, 0.001 
Yes, Yes 2.4 -0.03 -0.07, 0.01 -1.3 -0.03 -0.05, -0.004 
No, Yes -5.1 -0.01 -0.14, 0.11 -4.7 -0.01 -0.08, 0.06 
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